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General Introduction 
 
HIV/AIDS has become a devastating epidemic affecting about 40 million people 
worldwide (1). Most of the infected individuals are from low-income countries 
whereby sub-Saharan Africa, accounts for over 70% of the world’s HIV cases. 
(2). HIV infection rate is still increasing and it was estimated that a total of 4.3 
million (3.6 – 6.6 million) new HIV infections occurred worldwide in 2006. In that 
same year, 2.8 million (2.4 – 3.2 million) new HIV infections and 2.1 million 
AIDS-related death cases occurred in sub-Saharan Africa, the latter representing 
72% of global AIDS-related death (3). In Tanzania, it was estimated that over 
1.4 million (1.3 – 1.6 million) persons were living with HIV by the end of 2005, 
making Tanzania one of the most affected countries in the world (3). It was 
projected that by the year 2010, in Tanzania new HIV infections and AIDS death 
will increase steadily to reach respectively 250,000 and 120,000 cases per year 
(4). 
 
Oral lesions are important in the context of HIV since these lesions often occur at 
an early stage which indicates the presence of HIV infection, predicts the 
progression of HIV to AIDS, and causes significant morbidity (5-10). Several 
HIV-associated oral lesions have been notified such as oral candidiasis, oral hairy 
leukoplakia, herpetic gingival stomatitis, herpes simplex virus (HSV) stomatitis, 
aphthous ulcers, acute necrotizing ulcerative gingivitis (ANUG), oral Kaposi’s 
sarcoma, oral warts-human papilloma virus and salivary gland diseases (5-10). 
Mucocutaneous candidiasis is however the most common oral manifestation of a 
HIV infection (5–12). Gastro-intestinal candidiasis may affect either the oral 
cavity (oral candidiasis), the oral-pharynx (oropharyngeal candidiasis) or 
esophagus (esophageal candidiasis).  
 
Oral candidiasis occurs in up to 90% during the course of HIV disease (5–12). 
Oral candidiasis was included in the first descriptions of AIDS (13) and is now 
incorporated in all stages and classifications of HIV infection (14,15). Clinically 
there are different forms of oral candidiasis in HIV infection, the most frequent 
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form is pseudomembranous candidiasis, others are erythematous candidiasis, 
angular cheilitis and rarely hyperplastic candidiasis (16). Some studies have 
found differences in prognostic significance of the various clinical forms of oral 
candidiasis (17,18). The occurrence of the pseudomembranous variant has been 
associated with more severe immunosuppression than the erythematous variant 
and angular cheilitis (17). In general, the occurrence of oral candidiasis is 
associated with CD4 T-lymphocyte counts below 200 cells/mm3, high viral loads 
and disease progression (6,12). It should be noted however, that some patients 
suffer from recurrent oral Candida infections with relatively high CD4+ cell 
numbers, while other HIV-infected subjects do not develop this condition, despite 
severe immunodeficiency. Defects in innate immunity may contribute to this 
phenomenon since the role of the innate immunity (Toll like receptors and the 
inflammasome) may become more apparent when adaptive immunity is failing.  
 
Oral candidiasis can cause considerable discomfort to patients, adding to the 
burden of adverse social, psychological, and physical effects of advancing HIV 
infection. Furthermore, oral candidiasis lesions may extend to the pharynx and 
esophagus resulting in oropharyngeal and esophageal candidiasis respectively. 
This may prevent the intake of adequate nutrition, resulting to increased 
morbidity and reduce the length and quality of life (19). Esophageal candidiasis is 
usually seen in HIV infected patients when CD4+ cell counts are below 100 
cells/mm3, and is qualified as an AIDS defining condition (17).  
 
In Tanzania, oral manifestations of HIV are common and oral candidiasis is the 
commonest oral condition encountered in HIV infected patients with a prevalence 
of 12% to 44% in the period prior to the antiretroviral therapy era (HAART) 
(6,7,10).  No information is available on the prevalence of oral manifestations of 
HIV in the present HAART era. The present guidelines of the Tanzania Ministry of 
Health for management of candidiasis include miconazole ointment, clotrimazole 
oral troches, 2% sodium benzoate solution, gentian violet solution, nystatin oral 
suspension, ketoconazole and fluconazole. The guidelines do not provide ranking 
of 1st line or 2nd line drugs and this may have contributed, at least partly, to the 
adhoc management of oral candidiasis, whereby the choice for an antifungal 
agent primarily depends on the prescription preference of the attending physician 
and availability of the agents in the (hospital) pharmacy.  
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With liberalization of trade in Tanzania, several new antifungal agents became 
available, probably also over the counter. Besides, in 2004, the Tanzanian 
government has started a nation-wide distribution of fluconazole at no cost, 
which resulted in a rise of the prescription and utilization of this drug. The 
guidelines recommend a dosage of 150 mg/day or 200 mg/day for oropharyngeal 
candidiasis and esophageal candidiasis for a period of 2-3 weeks (20). The 
duration of treatment seems not well defined and probably varies significantly in 
daily practice. Optimalisation of recommendations for drug regimens is therefore 
required.  
 
The extensive use of antifungals, like fluconazole creates a potential for 
resistance development and shifts from a predominance of Candida albicans to 
non-albicans Candida species and it may induce refractory and recurrent 
infections (21–23). So far, information was missing regarding the etiological 
Candida species, their in vitro susceptibility to antifungal agents and treatment 
success of commonly used antifungal agents.  
 
Finally, in many parts of the world and Tanzania in particular, herbal medicines 
are often used for the treatment of various diseases including fungal infections 
(24-25). The scientific evidence for efficacy of these herbal plants is, however, 
lacking. These medicinal herbs are often widely available and could potentially 
offer a cheap alternative therapy. Therefore, further studies are needed that 
explore the efficacy of Tanzanian herbs that are used traditionally for the 
treatment of fungal infections and to provide scientific evidence that would 
support its use.  
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Aim of the thesis 
 
 
 To determine and compare the prevalence and  types of HIV-related oral 
lesions in children and adult Tanzanian patients on antiretroviral therapy 
(HAART) and those not on HAART and to determine the association 
between the occurrence of the lesions with HAART regimens, clinical stage 
of HIV disease and CD4+ cell counts.  
 To determine the species distribution of isolates obtained from Tanzanian 
HIV-infected patients with primary and recurrent oropharyngeal 
candidiasis and their susceptibility profiles to antifungal agents and to 
compare susceptibility profiles of isolates from treatment naive patients 
and repeatedly antifungal exposed patients. 
 To identify and obtain information on the plants that is used by traditional 
healers in the management of fungal infections and to determine their in-
vitro antifungal activity against yeasts. 
 To determine the clinical and mycological efficacy of two different 
fluconazole dosage regimens (single dose versus standard two weeks 
dose) for the treatment of oropharyngeal candidiasis in HIV infected 
patients. 
 To determine the role of genetic variations in Toll-like receptors 4 (TLR4), 
MyD88 adapter-like (MAL) and Caspase-12 towards presence of 
oropharyngeal candidiasis in HIV-infected patients in Tanzania. 
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Abstract 
Background 
The aim of the study was to compare the prevalence and types of HIV-related 
oral lesions between children and adult Tanzanian patients on HAART with those 
not on HAART and to relate the occurrence of the lesions with anti-HIV drug 
regimen, clinical stage of HIV disease and CD4+ cell count. 
Methods 
Participants were 532 HIV infected patients, 51 children and 481 adults, 165 
males and 367 females. Children were aged 2- 17 years and adults 18 and 67 
years. Participants were recruited consecutively at the Muhimbili National 
Hospital (MNH) HIV clinic from October 2004 to September 2005. Investigations 
included; interviews, physical examinations, HIV testing and enumeration of 
CD4+ T cells.  
Results 
A total of 237 HIV-associated oral lesions were observed in 210 (39.5%) 
patients. Oral candidiasis was the commonest (23.5%), followed by mucosal 
hyperpigmentation (4.7%). There was a significant difference in the occurrence 
of oral candidiasis (χ2 = 4.31; df = 1; p = 0.03) and parotid enlargement (χ2 = 
36.5; df = 1; p = 0.04) between children and adults.  Adult patients who were on 
HAART had a significantly lower risk of; oral lesions (OR = 0.32; 95% CI = 0.22 
– 0.47; p = 0.005), oral candidiasis (OR = 0.28; 95% CI = 0.18 – 0.44; p = 
0.003) and oral hairy leukoplakia (OR = 0.18; 95% CI = 0.04 – 0.85; p = 0.03). 
There was no significant reduction in occurrence of oral lesions in children on 
HAART (OR=0.35; 95% CI =0.11-1.14; p = 0.15). There was also a significant 
association between the presence of oral lesions and CD4+ cell count < 200 
cell/mm3 (χ2 = 52.4; df = 2; p = 0.006) and with WHO clinical stage (χ2 = 121; df 
= 3; p = 0.008). Oral lesions were also associated with tobacco smoking (χ2 = 
8.17; df = 2; p =0.04). 
Conclusions 
Adult patients receiving HAART had a significantly lower prevalence of oral 
lesions, particularly oral candidiasis and oral hairy leukoplakia. There was no 
significant change in occurrence of oral lesions in children receiving HAART. The 
occurrence of oral lesions, in both HAART and non-HAART patients, correlated 
with WHO clinical staging and CD4+ less than 200 cells/mm3.  
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Background 
Most African studies on HIV associated oral lesions have been done during pre- 
HAART era (1–11). The relatively few studies of oral lesions in patients on HAART 
have been conducted elsewhere and do indicate significant differences in the 
influence of HAART on types of oral lesions (12–14). For example, oral 
candidiasis, oral hairy leukoplakia, Kaposi’s sarcoma and HIV-associated 
periodontal diseases have been reported to decrease (12,13,15–22). On the 
other hand, HIV-salivary gland disease, human papilloma virus (HPV)-associated 
oral lesions including papilloma, condylomas and focal epithelial hyperplasia [oral 
warts], xerostomia and recurrent oral ulceration appear to have increased (13–
15,18,23–25). There are also reports indicating no change in the occurrence of 
HIV associated oral lesions in children receiving HAART (26,27). The reasons for 
these differences are not entirely clear. Some authors have associated these 
variations with differences in access to oral health care, demographic and social 
factors, mode of HIV transmission, types of co-infections, disease stage and 
immune reconstitution (18,28,29). Nonetheless, the presence of such significant 
differences underlines the need for meticulous monitoring of prevalence and 
types of HIV associated oral lesions in every clinical setting that provide HAART 
(13). 
 
As indicated earlier, most of the above-mentioned studies have been conducted 
in developed countries (30,31). There is relatively little information emanating 
from developing countries, where particular efforts are being made to scale up 
provision of HAART to eligible patients (32). 
The government of Tanzania, with assistance from international donor agencies, 
started providing HAART to HIV patients free of charge in July 2004 (33,34). 
However, there is no information regarding human immunodeficiency virus 
(HIV)-related oral lesions of patients on antiretroviral therapy. This study aimed 
to determine the prevalence and types of oral manifestations of HIV/AIDS 
between children and adult patients on HAART and those not on HAART, and 
correlate clinical oral lesions with clinical stage of HIV disease, anti-HIV drug 
regimen and CD4+ cell count.    
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Methods 
Participants and setting 
A total of 532 HIV-infected patients, 367 (69%) females and 165 (31%) males 
participated in the study. There were 51 children aged between 2 and 17 years, 
with mean age of 7.6 (SD ± 4.3) years and 481 adults aged 18-67 years, with a 
mean age of 38.2 (SD ± 8.9) years.  Participants were recruited consecutively at 
the Muhimbili National Hospital (MNH) HIV clinic in Dar es Salaam, from October 
2004 to September 2005. The MNH is the largest referral hospital in Tanzania 
and serves as a teaching facility for the Muhimbili University College of Health 
Sciences (MUCHS), the largest medical school in the country.  
 
Study design and sample size calculations 
This was a cross sectional study. The sample size was estimated at 336, by 
assuming the prevalence of oral lesions in HIV infected individuals in Tanzania to 
be around 30% (4) and by setting type I error at 5% and type II error at 20%. 
We consecutively enrolled 532 patients. None of the patients declined 
participation in this study, bringing the participation rate to 100%. 
 
Investigations 
Patients were interviewed using a standard structured questionnaire to obtain 
information regarding social and demographic details, past medical history, 
family history and history of previous medication. Previous episodes of oral 
candidiasis, other medical conditions, use of traditional medicine, anti-
tuberculosis drugs, antifungal agents, and use of antiretroviral and current 
treatments were all recorded. Current and previous episodes of opportunistic 
systemic diseases related to HIV were categorized and recorded as follows: 
tuberculosis, pneumonia, herpes zoster infection and cryptococcal meningitis. 
 
General examination 
Clinical examination of all study patients was done by an independent physician, 
who categorized them in accordance with the World Health Organization (WHO) 
clinical staging criteria (35).  
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Oral examination 
An oral examination was carried out by a qualified dental surgeon without 
knowing the HIV clinical stage and CD4+ cell count level of the patient or 
whether the patient was on HAART or not. A standard oral examination method 
recommended by WHO (36) was used to examine: (a) the extra-oral, head and 
neck areas; and (b), peri-oral and intra-oral soft tissues using a criteria described 
by Greenspan et al. (37). Examination was conducted while the patient was 
seated on a chair under artificial light. The extra-oral and peri-oral tissues were 
examined first, followed by the intra-oral tissues, for changes in size, colour and 
shape of anatomical areas as well as for clinical signs and lesions. The oral 
lesions associated with HIV infection were diagnosed based on their clinical 
presentation and where multiple sites were involved, all sites were documented.  
 
HIV serology and determination of lymphocytes subsets 
Blood was collected in EDTA tubes from the patients. HIV serology was 
determined by Vironostika HIV Uni-Form II Ag/Ab (BioMerieux, Boxtel, The 
Netherlands) and reactive samples were retested by Vironostika HIV Uni-Form II 
Plus O (BioMerieux, Boxtel, The Netherlands). Samples reactive on both tests 
were considered to be positive for IgG anti HIV antibodies. Enumeration of CD4+ 
and CD8+ T cells was done using FACS count machine after staining patients’ 
blood with monoclonal antibodies (38).  
 
HAART regimens 
In Tanzanian setting, a triple therapy consisting of 2 nucleoside reverse 
transcriptase inhibitors (NRTI) + 1 non- nucleoside reverse transcriptase 
inhibitors (NNRTI) or 2 NRTI + 1 Protease inhibitor (PI) is recommended. The 
first line includes four different combinations of drugs: stavudine + lamivudine + 
nevirapine; stavudine + lamivudine + effavirenz; zidovudine + lamivudine + 
nevirapine and zidovudine + lamivudine + effavirenz. The second line regimen 
includes the following drug combination: Abacavir + kaletra (lopinavir/ritonavir) 
+ didanosine and abacavir + saquinavir/ritonavir + didanosine (34). 
 
Ethical issues 
The study protocol was approved by the ethics committees of the Muhimbili 
University College of Health Sciences and Muhimbili National Hospital, Dar es 
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salaam, Tanzania. Informed verbal consent was sought from participants and 
from parents/or guardians in case of children below eighteen years. The following 
information was given to ensure that patients and parents/guardians have the 
information needed to make an informed choice: a complete description of the 
aims of the study, potential benefits and risks, blood collection procedures and 
assurance of confidentiality of any information given as well as test results. 
Study personnel provided any other requested additional information. All patients 
seen in this study received appropriate care and treatment according to national 
guidelines on care and treatment of HIV infected individuals. Patients who were 
found to have any oral lesions were referred to the Department of Oral Surgery 
and Oral Pathology of the Muhimbili National Hospital where appropriate 
management and follow-up were given. All patients’ information and test results 
were confidentially kept.  
 
Statistical analysis 
Data were coded, entered, cleaned, validated and analyzed using the SPSS 
version 12.0 (39).  Patients were categorized into children (<18 years) and 
adults (≥18 years) and into those on HAART and those not receiving HAART. 
Comparison of proportions was performed using the Pearson chi-squared test 
and in situation where 20% or more of the cells had expected count less than 5, 
Fisher’s exact test was used. Bivariate analysis was done using Spearman’s rank 
correlations. A P-value of < 0.05 was considered significant. The following were 
determined: degree of associations between occurrence and types of oral lesions 
and use of anti-retrovirals, gender, smoking habits, alcohol consumption, 
coexistence with opportunistic systemic diseases, clinical stage of HIV disease 
and degree of immunosuppression. Multiple logistic regression analysis was 
performed to assess the association between presence of oral lesion associated 
with HIV and use of antiretrovirals after adjusting for CD4+ cell count.  
 
 
Results 
A total of 532 HIV-infected patients, 367 (69%) females and 165 (31%) males 
participated in the study (Table 1). There were 51 children aged between 2 and 
17 years, with mean age of 7.6 (SD ± 4.3) years and 481 adults aged 18-67 
years, with a mean age of 38.2 (SD ± 8.9) years. Overall, median CD4+ cell 
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count was 151 cells/mm3, with values ranging from 1 to 2007 cells/mm3. The 
median CD4+ cell count for children was 501 cells/mm3 and 134 cells/mm3 for 
adults. Majority 373 (70.1%) of children and adult patients were in the WHO 
clinical stages II to III. Among the participants, 298 (56%) patients were on 
HAART, consisting of nucleoside reverse transcriptase inhibitors (NRTIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors 
(PIs). Majority 297 (99.7%) were on the first line HAART combination, of whom 
229 (76.8%) were on a combination of Stavudine/Lamivudine/Nevirapine, 32 
(10.7%) on a combination of Zidovudine/Lamivudine/Effavirenz, 26 (8.7%) on 
Stavudine/Lamivudine/Effavirenz and 10 (3.4%) were on Zidovudine/ 
Lamivudine/ Nevirapine. One patient (0.3%) was on second line combination that 
included protease inhibitors (Abacavir/Lopinavir/ Didanosine). Two hundred and 
thirty four (44%) patients were not receiving HAART. Sixty-two patients (11.7%) 
reported use of traditional medicines, of whom 36 (58%) were concomitantly 
using traditional medicines with HAART.  
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Table 1: Socio-demographic, treatment, WHO clinical stage and CD4 cell counts of study 
participants  
 
Characteristics All patients  
n (%)  
Patients with 
oral lesions  
 n       (%)*  
χ
2
-
value      
p- 
value** 
Gender     
Male   165 (31.0)  63      (38.2)  0.17           0.68 
Female                               367     (69.0)  147     (40.1)    
Age (Years)     
Children 2-17 51       (9.6) 21       (41.2) 0.68 0.88 
Adults  18 - 67 481     (90.4) 189     (39.3)   
Smoking habit     
Current    20     (3.8) 14       (70) 8.17           0.02 
Stopped   17     (3.2) 7        (41.2)   
Never    495     (93.0)  189    (38.2)   
Alcohol consumption     
Current   31     (5.8)  10     (32.3)   
Stopped   37     (7.0)  16     (43.2) 0.90 0.64 
Never    464     (87.2)  184    (39.6)   
Traditional medicine     
Yes   62    (11.7) 25     (40.3) 0.17            0.68 
 No 470    (88.3) 183   (38.9)   
Antiretroviral therapy     
Without therapy  234    (44.0) 127   (54.3)  38.30 0.00     
HAART therapy  298     (56.0) 83    (27.9)   
Antiretroviral types     
Stav/Lamiv/ Nev  229   (76.8) 9      (12.9) 2.96           0.57                
Stav/Lamiv/ Eff   26    (8.7) 10    (38.5)   
Zido/Lamiv/Eff    32    (10.7) 11     (34.4)   
Zido/Lamiv/Nev   10    (3.4) 2      (20.0)   
Abac/Lop/Didan     1    (0.3) 0       (0)   
WHO HIV clinical stage     
Stage I   70      (13.2) 9      (12.9)   
Stage II 204     (38.3)  38    (18.6) 120.93        0.00     
Stage III 169     (31.8)  101   (59.8)   
Stage IV   89     (16.7) 62    (69.7)   
CD4+ cell count 
(cells/mm3) 
    
> 500   46       (8.6) 10    (21.7)   
200-500 164     (30.8) 33    (20.5) 52.45         0.00 
< 200  322     (60.5)  167   (31.9)   
Total number of patients  532     (100.) 210   (39.5)   
 
* Row percentages; ** p-value less than 0.05 was considered significant; χ
2 Chi square 
test 
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A total of 237 HIV-associated oral lesions were observed in 210 (39.5%) 
patients. Overall, oral candidiasis was the commonest oral lesion seen in 125 
(23.5%) patients followed by mucosal hyper pigmentation 25 (4.7%), parotid 
gland enlargement 21 (3.9%) and oral Kaposi’s sarcoma 17 (3.2%) (Table 2). In 
children, parotid gland enlargement was the commonest oral lesion (19.6%), 
followed by oral candidiasis (11.8%), oral Kaposi’s sarcoma (3.9%), oral hairy 
leukoplakia (3.9%), herpes simplex lesions (2.2%) and oral warts was the least 
(2.0%). In adults, oral candidiasis was the commonest (24.7%), followed by 
mucosal hyperpigmentation (5.2%), herpes zoster face and odontogenic abscess 
was the least (0.4% each). There was statistically significant difference in the 
occurrence of oral candidiasis (χ2 = 4.31; df = 1; p < 0.05) and parotid 
enlargement (χ2 = 36.5; df = 1; p < 0.05) between children and adults.  
Pseudomembranous candidiasis was the most predominant type of oral 
candidiasis 66.4% (83/125) followed by a combination of pseudomembranous 
and erythematous 12% (15/125), erythematous candidiasis 9.6% (12/125), 
angular cheilitis 3.2% (4/125), combination of angular cheilitis with 
erythematous and hyperplastic variant were the least (1.6% each). Among 125 
patients diagnosed with oral candidiasis 42 (33.6%) patients had previous history 
of oral candidiasis, 37 (29.6%) patients presented with esophageal symptoms 
such as dysphagia, odynophagia and chest pain at the time of examination.  
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Table 2: Occurrence of HIV-associated oral lesions among children and adults 
 
 
 
 
Table 3 shows no significant difference in prevalence of oral lesions among 
children on HAART and those not on HAART (OR = 0.35; 95% CI = 0.11 – 1.15; 
p > 0.05). Table 4 shows that adult patients who were on HAART had a 
significantly lower risk of oral lesions (OR = 0.32; 95% CI = 0.22 – 0.47; p < 
0.01), oral candidiasis (OR = 0.28; 95% CI = 0.18 – 0.44; p < 0.01) and oral 
hairy leukoplakia (OR = 0.18; 95% CI = 0.04 – 0.85; p < 0.03). There was also 
lower prevalence of necrotizing ulcerative gingivitis, herpes simplex lesions, 
recurrent ulcers, Bell’s palsy and herpes zoster of face in adult patients who were 
on HAART, but the difference was not statistically significant (p > 0.05).  After 
controlling for CD4+ cell count, adult on HAART had a significantly lower risk of 
oral Kaposi’s sarcoma compared with those not on HAART (adjusted OR= 0.29; 
95% CI= 0.10-0.89; p < 0.03). The odds for oral warts and mucosal hyper 
pigmentation were non-significant higher in adult who were on HAART, being (OR 
= 1.49; 95% CI = 0.13 – 16.5; p > 0.05) and (OR = 1.62; 95% CI = 0.68 – 
3.82; p > 0.05), respectively.  
 
Oral lesion Children (2-17yrs) 
 n (%) 
Adults (18-67 yrs) 
 n (%) 
     Total (n=532) 
 n (%) 
Oral candidiasis  6 (11.8)  119 (24.7)  125 (23.5) 
Hyperpigmentation  0 (0)  25 (5.2)  25 (4.7) 
Enlarged Parotid 
gland 
 10 (19.6)  11 (2.3)  21 (3.9) 
Oral Kaposi’s 
sarcoma 
 2 (3.9)  15 (3.1)  17 (3.2) 
Necrotizing 
Ulcerative gingivitis 
 0 (0)  13 (2.7)  13 (2.4) 
Oral hairy 
leukoplakia 
 2 (3.9)  10 (0.6)  12 (2.3) 
Herpes simplex 
lesions 
 7 (2.2)  2 (2.1)  9 (1.7) 
Recurrent ulcers  0 (0)  4 (0.8)  4 (0.8) 
Oral warts  1 (2.0)  3 (0.6)  4 (0.8) 
Bell’s palsy  0 (0)  3 (0.6)  3 (0.6) 
Herpes zoster face  0 (0)  2 (0.4)  2 (0.4) 
Odontogenic abscess  0 (0)  2 (0.4)  2 (0.4) 
All oral lesions  21    (41.2)  189   (39.3)  210   (39.5) 
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 The duration of use of HAART ranged from 1 to 14 months, with majority 
(71.1%) having been on treatment for one to six months. Patients on HAART for 
the duration of more than six months had significantly lower prevalence of oral 
lesions (OR = 0.53; 95% CI 0.29-0.97; p < 0.05) and specifically oral candidiasis 
(OR = 0.53; 95% CI 0.29-0.97; p = 0.04).  
 
 
 
Table 3: Comparison of oral lesions among children on HAART (n=22) and those not on 
HAART (n=29) 
 
Type of oral lesions  No. of oral 
lesions                                                  
n         (%)                 
Unadjusted 
OR (95%CI)            
Adjusted OR  
(95% CI)      
p-value 
Oral candidiasis     
On HAART                    
Not on HAART               
0       (0.0)                       
6        (20.7) 
0.0 (0.0-9.20) 0.0 (0.0-1.80) 0.80 
Enlarged Parotid gland     
On HAART                      
Not on HAART  
4 (18.2) 
6       (20.7) 
0.8 (0.2-3.48) 0.9 (0.22-3.93)      0.82 
 
Oral Kaposi’s sarcoma 
 
    
On HAART        
Not on HAART  
1         (4.5)                           
1      (3.4) 
1.3 (0.08-22.6) 0.9 (0.05-17.4) 0.84 
 
Oral hairy leukoplakia     
On HAART                      
Not on HAART  
0 (0.0)       
10        (6.9)  
0.0 (0.0-2.61) 0.0 (0.0-2.11) 0.88 
Herpes simplex lesions     
On HAART      
Not on HAART                                       
0         (0.0)             
1         (3.4)  
0.0 (0.0-1.52) 0.0 (0.0-7.30) 0.92 
Oral warts 
 
    
On HAART                       
Not on HAART                  
1         (4.5)                                          
0         (0.0)  
-   - 0.91 
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Table 4: Comparison of oral lesions among adults on HAART (n=276) and those not on 
HAART (n=205) 
 
Type of oral lesions  No. of oral 
lesions                                                  
n         (%)                 
Unadjusted OR 
(95% CI)   
Adjusted OR  
(95% CI)      
p-value 
Oral candidiasis     
On HAART                    
Not on HAART               
41       (14.9)                       
78       (38.0) 
0.28 (0.18-0.44) 0.17 (0.11-0.28) 0.00 
Hyper pigmentation     
On HAART      
Not on HAART  
17 (6.2) 
8      (3.9) 
1.62 (0.68-3.82) 1.60 (0.67-3.81) 0.27 
Enlarged Parotid gland     
On HAART                      
Not on HAART  
6 (2.2) 
5       (4.9) 
0.89 (0.27-2.95) 0.92 (0.27-3.10) 0.85 
Oral Kaposi’s sarcoma 
 
    
On HAART        
Not on HAART  
5         (1.8)                           
10       (4.9) 
0.36 (0.12-1.06) 0.29 (0.10-0.89) 0.06 
*(0.03) 
Necrotizing Ulcerative 
gingivitis 
    
  On HAART  5         (1.7)  0.45 (0.15-1.41) 0.37 (0.12-1.15) 0.17 
  Not on HAART                 8         (3.4)    
Oral hairy leukoplakia     
On HAART                      
Not on HAART  
2 (0.7)       
8        (3.9)  
0.18 (0.04-0.85) 0.15 (0.03-0.70) 0.03 
Herpes simplex lesions     
On HAART      
Not on HAART                                       
3         (1.1)             
5         (2.4)  
0.44 (0.10-1.86) 0.39 (0.09-1.69) 0.26 
 Recurrent ulcers          
On HAART                       
Not on HAART  
1         (0.4)             
3         (1.54) 
0.24 (0.02-2.37) 0.22 (0.02-2.15) 0.22 
Oral warts 
 
    
On HAART                       
Not on HAART                  
2         (0.7)                                          
1         (0.5)  
1.49 (0.13-16.5) 1.44 (0.13-16.4) 0.75 
Bell’s palsy     
On HAART                       
Not on HAART  
0      (0.0)     
 3        (1.5)  
          -          - 0.84 
Herpes zoster face     
  On HAART        
  Not on HAART                                    
  0        (0.0) 
2         (0.9)  
          -          - 0.85 
Odontogenic abscess      
On HAART                          1         (0.4)  0.74 (0.04-11.9) 0.78 (0.05-13.0) 0.83 
Not on HAART                    1         (0.5)     
 
* p-value obtained after adjusting for CD4+ cell counts. 
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The mean CD4+ profiles of patients on HAART and those not on HAART are 
shown in Table 5. Overall, the majority (67.8%) of patients who were on HAART 
had CD4+ cell count < 200 cells/mm3. Only small minority (32.2%) of the 
patients on HAART were found to have CD4+ counts > 200 cells/mm3. Among 
those who were not on HAART 51.3% had CD4+ cell count < 200 cells/mm3 while 
the rest in the group had CD4+ cell count > 200 cells/mm3.  However, the 
majority (70.3%) of adult patients on HAART had CD4+ cell count < 200 
cells/mm3 while only minority (36.4%) of the children on HAART had CD4+ cell 
count < 200 cells/mm3. The mean difference of CD4+ cell counts between the 
adult and children on HAART and those not on HAART was statistically significant 
(t = 3.94; 95% CI = 42.3 – 126.3; p < 0.01).  In both HAART and non-HAART 
receiving children and adult patients oral lesions occurred more significantly 
among those with CD4+ cell count less than 200 cells/mm3 (χ2 = 52.4; df = 2; p 
< 0.01). There was a strong association between the WHO clinical stage of HIV 
disease with the presence of oral lesions (χ2 = 121; df = 3; p < 0.01), 
particularly oral candidiasis (χ2 = 112; df = 3; p < 0.01), oral Kaposi’s sarcoma 
(χ2 = 121; d f = 3; p < 0.01), and oral hairy leukoplakia (χ2 = 10; df = 3; p < 
0.05).    
 
 
Table 5: CD4+ cell counts of Patients on HAART and those not on HAART 
 
 Patients on HAART (n=298) 
n    (%)       Mean     SD 
Patients without HAART (n=234) 
n     (%)         Mean       SD 
CD4+ cell count 
(cells/mm3) 
  
        <200 202 (67.8)     84.0      62.1 120  (51.3)       65.2              57.0 
        200-500   80 (26.8)     296.0     75.0   84    (35.9)      314.4   90.2 
        >500   16  (5.4)      714.1     207.1   30    (12.8)      879.9           415.2 
       Total   298             174.8     177.5 234                         259.1          310.0            
 
Student’s t-test for comparing means; (t = 3.94; 95% CI = 42.3 – 126.3; p = 0.00). 
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Eighty-four (15.8%) patients had current systemic diseases at the time of 
examination. Sixty-two (11.7%) patients had pulmonary tuberculosis (TB) and 
were on anti-tuberculosis treatment. Other systemic opportunistic diseases 
encountered at the time of examination were; pneumonia 14 (2.6%) patients 
and herpes zoster 8 (1.5%) patients. One hundred and thirty eight (25.9%) 
reported history of herpes zoster infection, 84 patients (15.8%) pneumonia while 
cryptococcal meningitis was reported by only 10 patients (1.9%).   There was a 
significant association between occurrence of pulmonary TB with oral lesions (χ2 
= 6.9; d f = 1; p < 0.01) and oral candidiasis (χ2 = 11.0; df = 1; p < 0.01) but 
not other systemic diseases (p > 0.05). Oral lesions were not associated with any 
of the investigated socio-demographic features except for tobacco smoking (χ2 = 
8.17; df = 2; p < 0.01).  
 
 
Table 6: Association in the occurrence of oral lesions and opportunistic systemic diseases 
among HIV-infected patients expressed as Odds ratios (OR) with 95% Confidence 
intervals 
 
Systemic 
disease 
n        (%) OR  (95% CI) χ
2
-value  (p- 
value) 
Tuberculosis 62     (11.7)   
   All oral lesions 
    
34      (54.8) 
 
2.02 (1.19-3.46) 6.9    (0.008) 
 
   Oral candidiasis                   25 (40.3) 2.50 (1.44-4.34) 11.0   (0.001) 
 
Pneumonia 14        (2.6) 
 
  
   All oral lesions   4     (28.6) 0.61 (0.19-1.96) 0.71  (0.40) 
 
   Oral candidiasis   2      (14.3) 0.54 (0.12-2.42) 0.68   (0.41) 
Herpes zoster                     8 (1.5) 
 
  
   All oral lesions   2      (25.0) 0.51 (1.01-2.53) 0.71  (0.32) 
   Oral candidiasis   2     (25.0) 1.08 (0.22-5.45       0.01  (0.60) 
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Discussion 
In the present study, the prevalence of HIV-associated oral lesions in adult 
patients receiving HAART was significantly reduced. The reduction was mainly 
attributed to the reduction of oral candidiasis and oral hairy leukoplakia among 
adult patients. This finding is consistent with observations in other studies that 
have shown significant reduction in these oral lesions associated with HAART 
usage, linked to the improved immune status of patients (12,13,15–22). 
Notably, patients on HAART for the duration of more than six months had 
significantly lower prevalence of oral lesions (OR = 0.53; 95% CI 0.29-0.97; p < 
0.05) and specifically oral candidiasis (OR = 0.53; 95% CI 0.29-0.97; p = 0.04). 
There was, however, no significant association between the type of HAART 
regimen and presence of oral lesions, most probably due to the fact that most of 
our patients (76.8%) were on one type of HAART consisting of stavudine, 
lamivudine and nevirapine, and that only one patient had a HAART combination 
containing PI. We found no significant difference in prevalence of oral lesions 
between children on HAART and those not on HAART (Table 3), similar to other 
studies (26,27).  The occurrence of HIV-associated oral lesions in children is an 
issue that requires further investigation as the results of different studies have 
produced conflicting results.  In one study there was no direct relationship 
between prevalence of oral lesions, severe immunodepression, and/or viral load 
> 100,000 copies in children who were perinataly infected with HIV (40).  
 
There were no significant difference in prevalence of oral lesions between adults 
(39.3%) and children (41.2%), (p > 0.05). However, a significantly higher 
prevalence of enlargement of parotid glands in children and oral candidiasis in 
adults was observed, which is in keeping with the findings of Greenspan et al. 
1992 (37).  
 
Mucosal hyperpigmentation, which was the second most prevalent oral lesions 
after oral candidiasis with a prevalence of 4.7%, occurred at higher, but non-
significant magnitude, among adult patients who were on HAART. The reported 
prevalence of mucosal hyperpigmentation compares with a prevalence of 6% 
among HIV/AIDS patients in Kenya (9). The higher prevalence of mucosal 
hyperpigmentation in patients on HAART has been linked with increased melanin 
production in the epithelium associated with increased release of ά –melanocyte-
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stimulating hormone (ά – MSH) (41) as a result of systemic ketoconazole and 
zidovudine therapy (42,43).  In the present study 20% (5/25) of patients with 
mucosal hyperpigmentation were on HAART combination containing zidovudine.  
 
Likewise, there was insignificant increase in oral papillomata [oral warts] in 
patients on HAART as compared to the non-HAART group. The increase in oral 
warts among patients on HAART has been associated with immune reconstitution 
(18,23–25).  The lack of significant association between oral wart and HAART 
usage observed in the present study could be due to the short period of the 
administration of HAART as majority of patients were on HAART for one to six 
months.  
 
There were no differences in the prevalence of other oral lesions including 
enlarged parotid glands, necrotizing ulcerative gingivitis, recurrent ulcers, Bell’s 
palsy and herpes zoster of the face between HAART and non-HAART groups (p > 
0.05). This could be explained by the fact that most of these lesions are classified 
as being less commonly associated with HIV (44) and therefore, their prevalence 
even in the non-HAART receiving group was small.   
 
The use of traditional medicine among our patients was high (11.7%), which is 
approximately one in eight patients, an observation that is in line with that 
reported earlier in Tanzania (45). Although no significant association was found 
between occurrences of oral lesions and use of traditional medicine (Table 1) 
there is still a need for further studies since many people with HIV/AIDS use 
traditional medicine in addition to HAART.  It is crucial to learn more about the 
nature and composition of these plant medicines and their potential interactions 
with drugs that are used for management of HIV/AIDS and its associated 
opportunistic diseases.  
 
In this study, 15.8% of patients diagnosed to have systemic diseases such as 
tuberculosis, pneumonia and herpes zoster at the time of examination. However, 
the only significant association found was between pulmonary TB and oral 
lesions, specifically oral candidiasis (p < 0.01) (Table 6). This association 
possibly reflects immune deterioration in patients with oral candidiasis and TB.  
This finding, which is in keeping with that of Nittayananta et al. 2002 (46) who 
 35 
found significant association between the occurrence of TB and the presence of 
oral candidiasis (OR 2.8; 95% CI 1.6–4.8; p < 0.01), and positive predictive 
values of any oral lesions and oral candidiasis in predicting TB of 87% (95% CI 
73.0–94.6) and 67% (95% CI 51.9–80.0), respectively seem to imply that oral 
candidiasis might be used as an additional clinical marker for TB together with 
clinical presentation of weight loss  with night sweats and chest symptoms. 
Majority (25.9%) reported history of herpes zoster infection, 84 patients (15.8%) 
pneumonia while cryptococcal meningitis was reported by only 10 patients 
(1.9%). However, there was no statistically significant difference between 
prevalence of oral lesions and history of opportunistic systemic diseases (p > 
0.05). The limitation on this part of the study was dependency on patients to 
recall previous opportunistic disease. 
 
Lastly, the significant association between occurrence of oral lesions with CD4+ 
counts < 200 cells/mm3 and WHO clinical stage of HIV disease (Table 1) found in 
this study underscores the prognostic significance of these manifestations in HIV 
disease. 
 
Conclusion 
In this group of HIV-infected patients, adult patients receiving HAART 
predominantly combination of stavudine, lamivudine and nevirapine for a period 
of less than a year, had a significantly lower prevalence of oral lesions, 
particularly oral candidiasis and oral hairy leukoplakia that was observed. There 
was also an insignificant increase in prevalence of oral warts and mucosal hyper 
pigmentation, while the prevalence of other oral lesions was unchanged. 
However there was no significant change in occurrence of oral lesions in children 
receiving HAART. More studies preferably longitudinal need to be conducted for 
longer periods of time in order to get a better picture on the efficacy of HAART in 
reducing oral lesions in both children and adults in our setting. 
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Abstract 
Background: In Tanzania, little is known on the species distribution and 
antifungal susceptibility profiles of yeast isolates from HIV-infected patients with 
primary and recurrent oropharyngeal candidiasis. 
Methods: A total of 296 clinical oral yeasts were isolated from 292 HIV-infected 
patients with oropharyngeal candidiasis at the Muhimbili National Hospital, Dar es 
Salaam, Tanzania. Identification of the yeasts was performed using standard 
phenotypic methods. Antifungal susceptibility to fluconazole, itraconazole, 
miconazole, clotrimazole, amphotericin B and nystatin was assessed using a 
broth microdilution format according to the guidelines of the Clinical and 
Laboratory Standard Institute (CLSI; M27-A2). 
Results: Candida albicans was the most frequently isolated species from 250 
(84.5%) patients followed by C.glabrata from 20 (6.8%) patients, and C.krusei 
from 10 (3.4%) patients. There was no observed significant difference in species 
distribution between patients with primary and recurrent oropharyngeal 
candidiasis, but isolates cultured from patients previously treated were 
significantly less susceptible to the azole compounds compared to those cultured 
from antifungal naïve patients.  
Conclusion: C.albicans was the most frequently isolated species from patients 
with oropharyngeal candidiasis. Oral yeast isolates from Tanzania had high level 
susceptibility to the antifungal agents tested. Recurrent oropharyngeal 
candidiasis and previous antifungal therapy significantly correlated with reduced 
susceptibility to azoles antifungal agents.  
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Background 
Oropharyngeal candidiasis (OPC) is the most frequent opportunistic infection 
encountered in human immunodeficiency virus (HIV) -infected individuals (1–4). 
It occurs in up to 90% at some point during the course of HIV disease (1,3,4). 
The occurrence of OPC is associated with CD4 T-lymphocyte below 200 
cells/mm3, high viral loads and disease progression (2,5,6). The prolonged 
course of HIV infection predisposes these patients to recurrent episodes of OPC 
that can increase in frequency and severity with progressive HIV disease (7). The 
advent of highly active antiretroviral therapy (HAART) has permitted suppression 
of viral replication and a partial recovery of CD4 T-lymphocyte count in HIV 
infected patients (8). Although the incidence and prevalence of opportunistic 
infections have been reduced worldwide due to use of HAART (9–12), OPC 
remains the most frequent HIV-associated oral lesion in most developing 
countries, including Tanzania (6).  
The prolonged management of OPC might cause the development of drug-
resistant OPC and there have been reports of emergence of resistance to 
antifungal agents in HIV/AIDS patients with OPC (13,14).  OPC due to resistant 
Candida isolates fails to respond to antifungal treatment with appropriate doses 
for a standard duration of time (15,16). The other possibility is that, repeated 
exposure to antifungal agents may predispose to a shift to non-albicans Candida 
species and associated refractory and recurrent infections (17–20).  However, a 
surveillance study done in the United Kingdom demonstrated that there was little 
difference in antifungal susceptibilities of Candida species isolated from 
immunocompetent patients who had a history of previous antifungal therapy 
compared with those who had not received antifungal treatment (21).  
 
OPC increases morbidity and mortality and reduces length and quality of life of 
HIV/AIDS patients, and therefore requires prompt diagnosis and adequate 
therapy. In vitro susceptibility testing is clinically useful in predicting which 
patients are likely to respond to therapy (22). In Tanzania, like many other 
developing countries, in vitro antifungal testing is not performed routinely 
(23,24). Therefore, little is known regarding the in vitro antifungal susceptibility 
of Candida species isolated from HIV-infected patients with OPC in Tanzania.  
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The aim of our study was to determine the species distribution of Candida 
isolates obtained from Tanzanian HIV-infected patients with primary and 
recurrent OPC. For each isolate the susceptibility profiles of six antifungal agents 
was determined and compared for treatment naive patients and repeatedly 
antifungal exposed patients. 
 
Methods 
Patients and setting 
Participants were recruited at the Muhimbili National Hospital (MNH) HIV clinic in 
Dar es Salaam, Tanzania from January 2006 to September 2007. Patients were 
eligible for the study if they were HIV-positive, 18 years of age and above with 
clinical picture of OPC, characterized by creamy, white, curd like patches, or by 
typical erythematous lesions on the oral or/and pharyngeal mucosa.  Patients 
were included after obtaining their written informed consent. Patients were 
interviewed using a standard structured questionnaire and their hospital records 
were also used to determine the previous episodes of OPC, use of antifungal 
agents and past medical conditions. A standard oral examination method 
recommended by WHO was used (25). Blood was collected in EDTA tubes from 
each patient for enumeration of CD4+ and CD8+ T cells using a fluorescent 
activated cell sorter (FACS) count machine after staining patients’ blood with 
monoclonal antibodies (26). Primary OPC was defined as the one that occur for 
the first time and recurrent OPC as the second episode and above during the 
course of HIV disease.  
 
Oral isolates and species identification  
Specimens were obtained by firmly swabbing the lesion site with sterile cotton 
wool swab (27). The swabs were cultured on sabouraud dextrose agar (SDA) 
(Oxoid Ltd, Hampshire, England) supplemented with 0.02% chloramphenicol and 
incubated aerobically at 30°C for 5 days. Isolates were identified to species level 
by colonial morphology on SDA and microscopic morphology. The germ tube 
production test was done. To distinguish between C.albicans and C.dubliniensis; 
all germ tube positive isolates were subcultured on SDA and incubated at 45°C 
aerobically and an isolate which did not grow at 45°C, was identified using 
AUXACOLOR 2 (Bio-Rad, France). Germ tube negative yeasts were identified 
using AUXACOLOR 2 (Bio-Rad, France) and the auxanographic method (28). In 
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the presence of multiple colony morphologies, all were identified to species level. 
After the final identification, isolates were stored at –80°C in 50% glycerol until 
susceptibility tests were performed. 
 
In vitro antifungal susceptibility testing 
The in vitro activities of fluconazole (Pfizer, Kent, UK), itraconazole, miconazole 
(Janssen-Pharmaceutica N.V., Beerse, Belgium), clotrimazole (Sigma Aldrich, 
Steinheim, Germany), amphotericin B (Bristol-Myers Squibb, Woerden, The 
Netherlands) and nystatin (Sigma Aldrich, Steinheim, Germany) were assessed. 
The minimum inhibitory concentration (MIC) was determined using a broth 
microdilution format (M27-A2) according to the guidelines of the Clinical and 
Laboratory Standard Institute (CLSI) (29), and all the testing done in duplicates. 
The respective manufacturers provided the antifungal agents as standard 
powders. Fluconazole was dissolved in sterile distilled water and itraconazole, 
miconazole, clotrimazole, amphotericin B and nystatin were dissolved in dimethyl 
sulfoxide (DMSO) to make stock solutions. RPMI 1640 medium with L-glutamine, 
without sodium bicarbonate (GIBCO BRL, Life Technologies, Woerden, The 
Netherlands) and buffered with morpholinepropanesulfonic acid (MOPS) at 
0.165M (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) was used as a test 
medium. Serial twofold dilutions and final dilutions of each antifungal agent were 
prepared in RPMI 1640 medium (29).  The range of fluconazole concentrations 
tested was 0.063–64 µg/ml and for itraconazole, miconazole, clotrimazole, 
amphotericin B and nystatin the range was 0.016–16 µg/ml. Aliquots of 100 µl of 
each antifungal agent at a concentration two times the targeted final 
concentration were dispensed in the wells of flat bottom 96-well microtiter plates 
(Costar, Corning, N.Y).  Prior to testing, isolates were subcultured on SDA at 
30ºC under aerobic conditions for 24 hours. Yeast inocula were prepared 
spectrophotometrically and further diluted in RPMI 1640 medium in order to 
obtain a final concentration of 0.5 to 2.5 x 103 CFU/ml (29). A constant volume 
(100 µl) of the innoculum was added to each microdilution well containing 100 µl 
of the serial dilution of the antifungal agents to reach final concentrations. The 
microtiter plates were incubated at 35ºC for 48 hours. 
 
The minimum inhibitory concentrations (MICs) were determined after 48 hours, 
after which readings were performed spectrophotometrically with a microplate 
 48 
reader (Anthos ht III; Anthos Labtec Instruments, Salzburg, Austria) at 405 nm 
using modified broth microdilution format (M27-A2) as described previously 
(21,30). The optical densities (ODs) of the blanks were subtracted from the ODs 
of the inoculated plates and the percentages of growth for each well were 
calculated. The MICs of polyene antifungals (amphotericin B and nystatin) were 
defined as the lowest concentrations that inhibit growth by 100%. The MICs of 
the azoles (fluconazole, itraconazole, clotrimazole and miconazole) were defined 
as the lowest concentrations that inhibit growth by 50%. Antifungal activity was 
expressed as the MIC of each isolate to the antifungal agent. The MIC values 
were the average of MICs of the first and duplicate measurement. The MIC 
values for fluconazole and itraconazole were compared to the CLSI interpretative 
guidelines on antifungal susceptibility testing. MICs of ≤ 8 µg/ml considered as 
susceptible, 16 – 32 µg/ml as susceptible dose dependent (SSD) and ≥ 64 µg/ml 
as resistant for fluconazole and for itraconazole, ≤ 0.125 µg/ml as susceptible, 
0.25 – 0.5 µg/ml as SDD and ≥ 1 µg/ml as resistant (29). American Type Culture 
Collection (ATCC) strains recommended by CLSI, C.parapsilosis (ATCC 22019) 
and C.krusei (ATCC 6258) were used as controls for each test. 
 
Ethical issues 
The Ethics Committees of the Muhimbili University of Health and Allied Sciences 
(MUHAS) and the Muhimbili National Hospital, Dar es salaam, Tanzania approved 
the study. All patient information and test results were confidentially kept.  
 
Data and statistical analysis 
The geometric mean of MICs, MIC50   and MIC90 were calculated. The MIC50   and 
MIC90 values were calculated as the concentrations of antifungals that were able 
to inhibit 50% and 90% of the isolates, respectively. The high and low off-scale 
MICs were included in the analysis by conversion to the next higher and lower 
drug concentrations, respectively. An isolate was considered resistant to 
fluconazole and itraconazole if average MICs were greater or equal to their 
respective CLSI breakpoints (29). Data were analyzed using the SPSS version 
14.0. Antifungal susceptibility of isolates from patients with primary OPC was 
compared with those of isolates from patients with recurrent OPC. Similarly, the 
antifungal susceptibility of isolates from patients who had not received an 
antifungal agent was compared with those of isolates from patients who had 
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previously received antifungal therapy. Comparison of species distribution and 
antifungal susceptibility rates was performed using Fisher’s exact test and Mann-
Whitney U-test. A P-value of < 0.05 was considered significant. 
 
Results 
Patients’ characteristics 
Two hundred and ninety two (292) HIV infected patients with OPC, 164 with 
primary OPC and 128 with recurrent OPC, participated in the study. 
Pseudomembranous candidiasis was the most predominant type of OPC 194 
(66.4%) followed by combinations of pseudomembranous and erythematous 66 
(22.6%), pseudomembranous and angular cheilitis 12 (4.1%), 
pseudomembranous and hyperplastic candidiasis 9 (3.1%), hyperplastic 
candidiasis 7 (2.4%) and erythematous candidiasis were the least 4 (1.4%). 
Patients’ ages ranged from 18 to 75 years, median 34 years of whom 218 
(74.7%) were females and 74 (25.3%) were males. The majority of the patients 
with recurrent OPC had a history of one previous episode of OPC (n = 92, 
71.8%) and the range of recurrences was 1 to 4 episodes. Their CD4+ T cells 
values ranged from 1 to 699 cells/mm3 with a median count of 93 cells/mm3 and 
229 patients (78.4%) had CD4+ T cells count below 200 cells/mm3. One hundred 
and seven patients (36.6%) were under HAART, predominantly (72.9%) a 
combination of stavudine, lamivudine and nevirapine and 65 patients (60.7%) 
were on HAART for duration below six months. 
 
Distribution of isolates 
Two hundred and ninety six (296) clinical oral yeasts were isolated from the 292 
patients with OPC. One hundred and sixty five (165) isolates were from patients 
with primary OPC and 131 isolates from patients with recurrent OPC. The species 
distribution as presented in Table 1 show that C.albicans was the most frequently 
isolated species (84.5%) followed by C.glabrata (6.8%) and C.krusei (3.4%). 
Saccharomyces cerevisiae was the only isolated non-Candida species from these 
patients. Four patients had mixed infection, two harbored C.albicans and C.krusei 
and two other patients had C.glabrata and C.krusei. Among four patients with 
mixed infection, three patients had recurrent OPC and one patient who harbored 
C.glabrata and C.krusei had primary OPC. There was no statistically significant 
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difference in species distribution between patients with primary and recurrent 
OPC (P = 0.264). 
 
Table 1: Distribution of oral yeast isolates among HIV-infected patients with primary and 
recurrent oropharyngeal candidiasis  
 
Species  Patients with Patients with All patients with 
primary OPC recurrent OPC primary and recurrent  
OPC  
   n (%)  n (%)  n (%) 
 
Candida albicans  141 (47.6)  109   (36.9)   250 (84.5) 
Candida glabrata  8 (2.7)  12 (4.1)  20 (6.8) 
Candida krusei  4 (1.35)  6 (2.05)  10 (3.4) 
Candida tropicalis 6 (2.02)  2 (0.68)  8 (2.7) 
Candida kefyr  3 (1)  - -  3 (1) 
Saccharomyces cerevisiae 2 (0.68)  1 (0.3)  3 (1) 
Candida pintolopesii - -  1 (0.3)  1 (0.3) 
Candida dubliniensis 1 (0.3)  - -  1 (0.3) 
Total of all isolates 165 (55.7) 131 (44.3) 296 (100) 
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In vitro susceptibility of isolates 
The results of antifungal susceptibility, as summarized in Table 2, show that only 
fifteen of the 296 isolates (5%) were resistant to fluconazole, while 20 (6.8%) 
isolates were susceptible dose dependent (SDD) and 261 (88.2%) of all tested 
isolates were susceptible to fluconazole. Twenty-five (8.4%) isolates were 
resistant to itraconazole, while 26 (8.8%) were SDD and 245 (82.8%) isolates 
were susceptible to itraconazole. Fluconazole exhibited greatest activity against 
C.albicans with no resistant strain found; overall five C.albicans isolates (2%) 
were SDD, while 245 (98%) were susceptible to this agent. All C.krusei isolates 
were resistant to fluconazole while 4 of the 8 (50%) C.tropicalis isolates were 
resistant to fluconazole. Only one of the isolated C.glabrata isolates (5%) was 
resistant to fluconazole, while six (30%) were fully susceptible and 13 (65%) 
were SDD. Moreover, all isolated C.kefyr, S.cerevisiae and C.dubliniensis isolates 
were fully susceptible to fluconazole, and the only isolated C.pintolopesii was 
SDD. Ten (4%) of the isolated C.albicans were resistant to itraconazole, while 
seven (2.8%) isolates were SDD and 233 (93.2%) isolates were susceptible to 
this antifungal agent. None of the C.glabrata isolated was fully susceptible to 
itraconazole, but 9 (45%) were SDD and 11 (55%) resistant. None of C.krusei 
isolates was resistant to itraconazole, while 5 (50%) isolates were SDD.  
C.pintolopesii was resistant while C.dubliniensis was fully susceptible to 
itraconazole. All the three S.cerevisiae isolates were SDD to itraconazole.  
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Table 2: In vitro antifungal susceptibility of all oral yeast isolates (n = 296) 
Species /Antifungal agent       MIC (µg/ml)         %R* 
 MIC Range MIC50  MIC90  GM  
  
C.albicans (250) 
        Amphotericin B 0.125 – 1 0.5  0.5  0.326   
        Nystatin  2 – >16 4  4  3.377   
        Fluconazole 0.063 – 32 0.25  2  0.330  0 
        Itraconazole 0.016 –>16 0.016  0.063  0.021  4 
        Miconazole 0.016 – 4 0.016  0.063  0.025   
        Clotrimazole 0.016 – 4 0.016  0.031  0.020 
C.glabrata (20) 
       Amphotericin B 0.5 – 1 0.5  1  0.545   
        Nystatin  2 – 4  4  4  3.668   
        Fluconazole 2 – 64  16  32  13.22  5 
        Itraconazole 0.016 – 4 1  4  0.615  55 
        Miconazole 0.063 – 0.5 0.25  0.5  0.189   
        Clotrimazole 0.125 – 2 1  2  0.474 
C.krusei (10) 
        Amphotericin B 0.5 – 1 1  1  0.683   
        Nystatin  2 – 8  4  4  0.965   
        Fluconazole 64 – >64 64  >64  76.1  100 
        Itraconazole 0.031 – 0.5 0.125  0.5  0.134  0 
        Miconazole 1 – 2  2  2  1.464   
        Clotrimazole 0.063 – 0.25 0.125  0.125  0.116 
 
C.tropicalis (8) 
        Amphotericin B 0.25 – 1 0.5  -  0.458   
        Nystatin  2 – 4  4  -  3.084   
        Fluconazole 1– >64 16  -  14.67  50 
        Itraconazole 0.016 – 2 0.5  -  0.176  37.5 
        Miconazole 0.125 – 4 2  -  0.840   
        Clotrimazole 0.031 – 4 2  -  0.337 
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Table 2 (Continued) 
Species /Antifungal agent       MIC (µg/ml)         %R* 
 MIC Range MIC50  MIC90  GM  
  
C.kefyr  (3) 
       Amphotericin B 0.5 – 0.5 0.5  -  0.5   
       Nystatin  2 – 4  2  -  2.244   
         Fluconazole 0.25 – 0.5 0.5  -  0.396  0 
       Itraconazole 0.016 – 0.031 0.031  -  0.019  0 
           Miconazole 0.016 – 0.016 0.016  -  0.016   
       Clotrimazole 0.016 – 0.016 0.016  -  0.016 
C.pintolopesii (1) 
        Amphotericin B 0.5   -  -  -    
        Nystatin  4  -  -  -   
        Fluconazole 16  -  -  -  0 
        Itraconazole 1   -  -  -  100 
        Miconazole 0.25  -  -  -   
        Clotrimazole 1   -  -  -   
C.dubliniensis (1) 
       Amphotericin B 0.25  -  -  -   
        Nystatin  4   -  -  -   
        Fluconazole 0.5   -  -  -  0  
        Itraconazole 0.016  -  -  -  0  
        Miconazole 0.016  -  -  -   
        Clotrimazole 0.016   -  -  -   
S.cerevisiae (3) 
        Amphotericin B 0.5 – 1 0.5  -  0.445   
        Nystatin  2 – 4  4  -  2.828   
        Fluconazole 8 – 8  8  -  8  0 
        Itraconazole 0.25 – 0.5 0.25  -  0.353  0 
        Miconazole 0.063 – 0.25 0.063  -  0.088   
          Clotrimazole 0.063 – 1 0.063  -  0.099 
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Table 2 (Continued) 
Species /Antifungal agent       MIC (µg/ml)         %R* 
 MIC Range MIC50  MIC90  GM  
  
All isolates (296) 
      Amphotericin B 0.125 – 1 0.5  0.5  0.352   
        Nystatin  2 – >16 4  4  3.39   
        Fluconazole 0.063 – >64 0.5  16  0.592  5 
        Itraconazole 0.016 – >16 0.016  0.5  0.031  8.4 
        Miconazole 0.016 – 4 0.031  1  0.036   
        Clotrimazole 0.016 – 4 0.016  1  0.029 
 
 
 
 
MIC50  – MIC value able to inhibit 50% of the isolates tested. 
MIC90   – MIC value able to inhibit 90% of the sample tested. 
GM   – Geometric Mean 
R*  – Percent resistance using interpretive breakpoint criteria of the CLSI (2002): 
Itraconazole resistance ≥1; Fluconazole resistance ≥ 64 µg/ml 
 
 
Correlation between MIC and recurrence of OPC 
In this study, among 292 patients investigated 173 patients (59.2%) had a prior 
history of antifungal usage, while 119 patients (40.8%) were antifungal 
treatment naïve. Therefore, 176 isolates (59.5%) were isolated from patients 
who had previous exposure to antifungal therapy (Table 3). Among patients 
exposed to antifungal therapy, 94 (54.3%) were exposed once, 47 (27.2%) twice 
and 32 (18.5%) were exposed three times and above. All patients with recurrent 
OPC had exposure to antifungal agents before enrollment in our study. Regarding 
patients with primary OPC, 45 (27.4%) were exposed to antifungal agents due to 
other fungal infections including vaginal candidiasis, skin fungal infections and 
cryptococcal meningitis. Most of patients had exposure to more than one 
antifungal agent, including fluconazole, clotrimazole, nystatin, miconazole and 
ketoconazole. Among exposed patients, 149 patients (86.1%) were exposed to 
azole compounds with fluconazole being the predominant (49.7%). 
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There were significant differences in the MIC distributions for isolates from 
patients with primary and recurrent OPC for amphotericin B (P = 0.041), 
itraconazole (P = 0.008), miconazole (P = 0.045), and clotrimazole (P = 0.013). 
No significant difference in MIC distribution between isolates was observed for 
nystatin (P = 0.608) and fluconazole (P = 0.133). Based on CLSI interpretative 
breakpoints, fluconazole resistance for species isolated from patients with 
primary OPC and recurrent OPC was noted in 9 isolates (5.5%) and 6 isolates 
(4.6%), respectively, which was not different (P = 0.581). However for 
itraconazole, more isolates cultured from patients with recurrent OPC exhibited 
reduced susceptibility compared with those cultured from patients with primary 
OPC (P = 0.03). 
However, when the correlation between in vitro susceptibility and previous 
exposure to antifungal agents was determined, it was found that all azole 
compounds tested were less active against Candida isolates cultured from 
patients who had been previously exposed to any antifungal drug compared with 
those cultured from the treatment naïve group (fluconazole, P = 0.037; 
itraconazole, P = 0.002; miconazole, P = 0.015; clotrimazole, P = 0.007). No 
significant differences in MICs of amphotericin B and nystatin between the two 
groups of isolates were noted (P = 0.087 and P = 0.117), respectively. 
 
In the present study, two of the five C.albicans isolates that were SDD to 
fluconazole were also SDD to itraconazole and three isolates were resistant to 
itraconazole. Itraconazole resistance was in 25 (8.4%) of all tested isolates, 
among which 17 isolates (68%) had MICs of ≥ 1µg/ml for clotrimazole. 
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Table 3. In vitro susceptibility of oral isolates to fluconazole and itraconazole as related 
to previous antifungal therapy 
 
Antifungal Previous antifungal (n = 176a)    No previous antifungal (n = 128b) P-value 
  S      SDD R  S      SDD  R   
 
Fluconazole 149 (84.7) 17 (9.7)  10 (5.7) 112 (93.3) 3 (2.5)    5 (4.2)  0.037 
 
Itraconazole  133 (75.6) 22 (12.5) 21 (11.9) 112 (93.3) 4 (3.3)    4 (3.3)  0.002 
 
 
Data are expressed as number of isolates (percentage). 
S – Susceptible, SDD – Susceptible dose dependent, R – resistant. 
Interpretive breakpoint criteria of the CLSI (2002): Fluconazole; S (MIC ≤ 8 µg/ml), SDD 
(MIC 16 –32 µg/ml), R (MIC 64 µg/ml) and Itraconazole; S (MIC ≤ 0.125 µg/ml), SDD 
(MIC 0.25 – 0.5 µg/ml), R (MIC ≥1). 
a C.albicans (143), C.glabrata  (19), C.tropicalis (4), S.cerevisiae (2), C.pintolopesii (1).                         
b C.albicans (107), C.glabrata (1), C.tropicalis (4), C.kefyr (3), S.cerevisiae (1), 
C.dubliniensis (1). 
 
 
Discussion 
The present study demonstrates that in Tanzania primary and recurrent OPC is 
predominantly caused by C.albicans. There was no significant difference in 
species distribution between the two groups of patients (P = 0.264). There are 
only a limited number of studies done in African countries regarding distribution 
of oral yeasts in HIV-infected patients. However, similar to our results, studies 
done in South Africa demonstrated that more than 80% of oral yeast isolates 
from HIV-infected patients were of the species C.albicans (23,31,32) that is not 
different to reports from other continents (19,33,34). On looking at distribution 
of isolates from patients with recurrent OPC and previously exposed to antifungal 
therapy, the current results are contrary to what was expected. Previously 
studies suggested that, repeated exposure to antifungal agents and recurrent 
infections might predispose to a shift to non-albicans Candida species (19,20). 
This was not the case in this study, which could be explained by the fact that, 
majority of the patients with recurrent OPC had only one previous episode of OPC 
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and among patients previously exposed to antifungal therapy almost a half were 
exposed only once. Interestingly, the first C.dubliniensis has been isolated from a 
Tanzanian HIV/AIDS patient with primary OPC and without previous history of 
antifungal therapy. Previous studies, reported that C.dubliniensis was primarily 
isolated from patients with previous antifungal therapy and/or recurrent OPC 
(35–37).  
 
In the present study, there appears to be a significant rapid induction of reduced 
susceptibility to azoles among oral yeasts isolated from patients with recurrent 
OPC and a previous history of antifungal therapy. This suggests that patients 
with more recurrent episodes of OPC and repeatedly exposed to antifungal 
therapies pose a great risk of reduced susceptibility to azole antifungal agents. 
Similarly, previous studies reported that prolonged exposure to antifungal 
therapy of these patients lead to reduced susceptibility of Candida species 
(17,19,38,39). Candida resistance to azole compounds has frequently been 
attributed to a selective pressure caused by antifungal agents and azole 
cumulative doses due to exposure to several courses of short- or long-term 
suppressive therapies in patients with OPC (38–40). Similarly, the risk of 
developing OPC with reduced susceptibility to azoles has been associated with 
greater duration of HIV infection and severe immunosuppression (20). 
 
Generally, even with the observed reduced susceptibility to azoles among oral 
yeast isolated from patients with recurrent OPC and previous history of antifungal 
therapy, in the present study resistance to antifungal agents among the tested 
isolates is relatively low. Resistance was mainly among non-albicans Candida 
species that are primarily or intrinsically resistant to azoles (19). Fluconazole 
resistance among all the tested isolates was 5%, which is similar to that reported 
by other previous studies (21,41). The reason for the low fluconazole resistance 
could be explained by the fact that, fluconazole was non affordable to most HIV 
patients until October 2004, when the government started to provide it for free 
to needy HIV-infected patients as standard of care. In general, antifungal drug 
prophylaxis is rarely practiced in Tanzania. In the present study, overall 
resistance of all tested isolates to itraconazole is 8.4%; slightly higher than that 
of fluconazole (5%). However, none of the investigated patients were exposed to 
this antifungal agent before, indicating possible cross-resistance following 
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exposure to other compounds from this class (42,43). A relation between azole 
resistance and previous azole exposure was found in this study, with patients 
who were previously exposed to antifungal therapy having isolates significantly 
more resistant to itraconazole and fluconazole than those from treatment naïve 
patients (P = 0.002) and (P = 0.037), respectively.  
 
There are no interpretative breakpoint criteria for nystatin, amphotericin B, 
miconazole and clotrimazole. However, the results of the present study have 
shown that MICs of miconazole, clotrimazole and amphotericin B was 
concentrated in a narrow range. Previous studies have shown low MICs of 
miconazole and amphotericin B against tested strains (17,21,24), which is in 
accordance with our findings. The Tanzanian guidelines for management of HIV 
and AIDS include fluconazole orally, miconazole, nystatin oral suspension, 2% 
Sodium benzoate solution or gentian violet solution and ketoconazole for 
oropharyngeal and esophageal candidiasis (44). Amphotericin B is used in topical 
forms as an oral suspension, but the drug is not available for this indication in 
Tanzania The present study would support the effectiveness of amphotericin B, 
miconazole, clotrimazole, itraconazole and fluconazole for treatment of OPC in 
HIV/AIDS patients. However, continuously surveillance programs are needed in 
order to identify possible changes in the species distribution, antifungal 
susceptibility patterns of oral yeasts and in vivo efficacy of these antifungal 
agents. 
 
Conclusions 
This study demonstrates that C.albicans is the most frequently isolated species 
from both patients with primary and recurrent OPC. Oral yeast isolates from 
Tanzania have high level susceptibility to fluconazole, itraconazole, miconazole, 
clotrimazole and amphotericin B.  Recurrent oropharyngeal candidiasis and 
previous antifungal therapy significantly correlated with reduced susceptibility to 
fluconazole, itraconazole, miconazole, and clotrimazole.  
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 Abstract 
 
Using the ethnobotanical approach, some Tanzanian plants reported to be used 
by traditional healers for the treatment of oral candidiasis and fungal infections of 
the skin were collected and screened for their antifungal activity against Candida 
albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida 
krusei and Cryptococcus neoformans.  
A total of 65 crude methanol extracts belonging to 56 plant species and 38 
families were screened using the broth microdilution method, according to the 
guidelines of the Clinical and Laboratory Standard Institute (CLSI) (formerly, 
National Committee for Clinical Laboratory Standards) [National Committee for 
Clinical Laboratory Standards, 2002. Reference Method for Broth Dilution 
Antifungal Susceptibility Testing of Yeasts. Approved Standard-2nd Edition M27-
A2, National Committee for Clinical Laboratory Standards, Wayne, PA, USA]. 
Among the tested plant species, 45% (25 species) showed antifungal activity 
against one or more of the test fungi. The most susceptible yeasts were 
Cryptococcus neoformans, followed by Candida krusei, Candida tropicalis, and 
Candida parapsilosis. The least susceptible were Candida albicans and Candida 
glabrata. Strong antifungal activity was exhibited by extracts of Clausena anisata 
Oliv., Sclerocariya birrea Sond, Turraea holstii Gurk, Sterculia africana (Lour) 
Fiori, Acacia robusta subsp. Usambarensis (Taub) Brenan, Cyphosterma 
hildebrandti (Gilg), Desc, Elaeodendron buchannanii (Lows), Acacia nilotica (L.) 
Wild ex Del, Jatropha multifida L., and Pteridium aquilinum (L.) Kuhn.  
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1. Introduction 
 
It has been shown that up to 90% of all HIV/AIDS patients contract fungal 
infections at some point during the course of the disease (Diamond, 1991) and 
that 10-20% die as a direct consequence of fungal infection (Drouhent and 
Dupont, 1989). Oral candidiasis is the earliest and most frequent fungal infection 
in the HIV-infected patients (Schiodt et al., 1990; Matee et al., 2000; Reichart, 
2003). This may extend to the oesophagus and prevent intake of adequate oral 
nutrition, resulting in increased morbidity and mortality, and reduction of the 
length and quality of life (Klein et al., 1984). Candida albicans is the most 
common causative agent of oral candidiasis, but non-albicans Candida spp., such 
as Candida tropicalis, Candida glabrata, Candida parapsilosis, Candida krusei, 
and Candida guilliermondii, have also emerged as significant pathogens 
(Powderly, 1992; Barchiesi et al., 1993).  Infection with the pathogenic fungus 
Cryptococcus neoformans is a more serious infection that often produces 
pneumonia and meningitis in HIV infected patients. Cryptococcus neoformans is 
estimated to have a prevalence of between 8 and 10% among the AIDS patients 
group (Brol et al., 2002). 
 
Management of candidiasis and other fungal infections, among HIV/AIDS 
patients, is facing a number of problems including resistance to antifungal 
agents, drug toxicity, high costs of antifungal agents and relapse of infections 
(Sangeorzan et al., 1994; Debruyne, 1997).  Literature reports show that HIV-
infected patients often develop resistance to treatment with fluconazole, the 
most currently used antifungal agent (Redding et al., 1994; Ruhnke et al., 1994; 
Goldman et al., 2005). Sometimes, resistance to fluconazole triggers cross-
resistance to other azoles or pathogen shift from Candida albicans to less 
sensitive species such as Candida glabrata and Candida krusei (Powderly, 1992; 
Bastert et al., 2001). This reduces the number of available, effective antifungal 
agents, thus necessitating the development of new antifungal remedies. 
 
Plants that are traditionally used in the treatment of fungal infections or related 
ailments could be a good source for new, safe, biodegradable and renewable 
antifungal drugs. This is an important possibility for Tanzania, where medicinal 
plants have been used for centuries. Both rural and urban populations still 
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depend on traditional healers for provision of health care. One report of a survey 
performed in Dar es Salaam showed that 21% of the people that went to seek 
care from public services had first consulted a traditional healer (Kilima et al., 
1993). Also according to Medicine du Monde, a French non-governmental 
organisation, in Kagera region five out of every six HIV-infected patients receive 
their medical attention from a traditional healer rather than from a hospital or 
primary health care facility (Anonymous, 1996). Despite the broad use of 
medicinal plants there is very limited scientific support for their use in the 
treatment of fungal infection. 
 
The purpose of this study was to identify and obtain information on the plants 
that are used by traditional healers in the management of fungal infections and 
to determine their in vitro antifungal activities against Candida spp. and 
Cryptococcus neoformans. 
 
2.  Materials and Methods 
2.1. Study areas 
The fieldwork was carried out in Tanga, Singida, Coast, and Morogoro regions 
located on northeast, central and eastern Tanzania in February-March 2004. 
Earlier studies reported that some plants used traditionally in these regions 
possess antifungal activity (Khan and Nkunya, 1991; Khan et al., 2000). The 
villages that were visited included Nyasa, (Mlalo ward, Lushoto district), on the 
western Usambara highlands with an altitude of 1341-1829 m. Mwaru, 
Nduamghangha and Mgori villages in Singida rural district bordering Mgori forest 
reserve, approximately 120 km from Singida town. Bwawani, and Mikese village 
(Morogoro region), Chamakwesa, Chalinze, Mabwepande, and Bagamoyo (Coast 
region). 
 
2.2. Interviews with traditional healers 
Information on the plants used for treatment of oral candidiasis and fungal 
infections of the skin, parts used, preparations, other uses and adverse effects 
were obtained through interviews with traditional healers using a questionnaire, 
after obtaining their informed consent. Interviews were conducted by the main 
author in Swahili language. Two traditional healers could only understand 
sukuma and shambaa language, respectively in which case close relatives 
 71 
assisted with translation during the interview. Fourteen traditional healers were 
interviewed, 11 men and 3 women. 
 
2.3. Collection and identification of plants 
Various plant parts such as leaves, whole plant, fruits, stem, stem barks, roots 
and root barks reported by interviewed traditional healers to be used for 
treatment of oral candidiasis and fungal infections of the skin were collected from 
the forest by the main and second author with the help of a traditional healer. 
The plants were identified at the Department of Botany, University of Dar es 
Salaam where also voucher specimens were deposited in the herbarium. 
 
2.4 Extraction of plant materials 
All plant samples were air-dried and ground. Approximately 400 grams of the 
plant materials were macerated with 80% methanol at room temperature and 
after 24 h filtered through Whatman number 1 filter paper. The procedure was 
repeated three times to ensure exhaustive extraction of the plant material. The 
extracts were pooled together, concentrated, and the solvent removed by 
evaporation under reduced pressure in a rotavapor at 40°C. The extracts were 
further dried by freeze-drying and kept in a freezer, at -20°C, until used for 
antifungal testing. 
 
2.5. Assay for antifungal activity  
The activity of the plant extracts were tested against six American Type Culture 
Collection (ATCC) yeast strains including; Candida albicans ATCC 90028, Candida 
glabrata ATCC 90030, Candida parapsilosis ATCC 22019, Candida krusei ATCC 
6258, Candida tropicalis ATCC 750, and Cryptococcus neoformans ATCC 90112. 
Candida spp. and Cryptococcus neoformans were subcultured onto Sabouraud 
dextrose agar (Oxoid Ltd., Hampshire England) and incubated at 35 °C for 24 
and 48 h, respectively.  
 
Testing of the plant extracts for antifungal activity was done by the broth 
microdilution method, according to the guidelines of the Clinical and Laboratory 
Standard Institute (CLSI) (formerly, National Committee for Clinical and 
Laboratory Standards) (NCCLS, 2002).  All the testing was done in duplicate. 
Stock solutions of dried methanol extracts were prepared by dissolving 100 mg 
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of each extract in 1 ml 100% dimethylsulfoxide (DMSO). The resulting 100 
mg/ml extract solutions were diluted 12.5 times in milli-Q water to obtain a 
concentration of 8 mg/ml. To avoid bacterial contamination each solution was 
sterilized by filtration through a 0.22 µm millipore-filter. Serial dilutions were 
made in RPMI-1640 medium with L-glutamine but without bicarbonate (GIBCO 
BRL, Life Technologies, Woerden, The Netherlands). Aliquots of 100 µL of the 
diluted extracts were dispensed into the wells of flat-bottomed 96-well microtitre 
plates (Costar, Corning, N.Y.).  
 
 The inocula were prepared spectrophotometrically (NCCLS, 2002) to give a final 
concentration of 0.5 - 2.5 x 103 CFU/ml in RPMI 1640 medium buffered to pH 7 
with 0.165M morpholinepropanesulfonic acid (MOPS). A constant volume (100 µl) 
of the inoculum was added to each microdilution well containing 100 µl of the 
serial dilution of the methanol extract to reach final concentrations of 4, 2, 1, 
0.5, 0.25, 0.125, 0.063, 0.031, 0.016 and 0.008 mg/ml, respectively. The 
microtiter plates were incubated at 350C for 48 h for Candida spp. and 72 h for 
Cryptococcus neoformans. DMSO 4-0.008% was used as growth control and 
amphotericin B was used as control against tested fungi. 
 
Minimum inhibitory concentrations (MICs) were determined after 48 h for Candida 
species and 72 h for Cryptococcus neoformans, after which readings were 
performed visually by comparing with growth in control wells and the extract blank, 
which consisted of uninoculated plates (the score of 0-4 was given) and 
spectrophotometrically with a microplate reader (Anthos htΙΙΙ; Anthos Labtec 
Instruments, Salzburg, Austria) at 405 nm. The optical densities (ODs) of the 
blanks were subtracted from the ODs of the inoculated plates and the percentage 
growth for each well was calculated. MICs of the extracts were defined as the 
lowest concentration of plant extract that visually showed no growth and 
spectrophotometrically percentage growth was less than 5% in comparison to that 
of growth control (MIC0). Minimum fungicidal concentrations (MFCs) were 
determined by subculturing each optically clear wells (no growth seen). Using a 
micropipette 50µL was removed from clear wells and inoculated onto SDA plates. 
The plates were then streaked with a sterile loop and incubated for 24-48 h at 
350C. The MFC was defined as the concentration of plant extract at which the 
number of colony forming units was zero (Hawser and Islam, 1999). 
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3.  Results and Discussion 
3.1. Ethnomedical information 
The results of the field study are presented in Table 1. A total of 65 plant parts 
belonging to 56 plant species and 38 families were reported to be used for 
treatment of oral candidiasis and fungal infections of the skin. The most 
represented family was Euphorbiaceae (six species), followed by Cucurbitaceae, 
Mimosaceae and Vitaceae (three species each).  Out of 56 plant species, three 
species were mentioned by two or more traditional healers. These included 
Clausena anisata Oliv (three times), Albizia anthelmintica (A.Rich) Brogn, and 
Rapanea melanophloeos (L) Mez (two times each). The methods of preparation 
and administration were generally topical (plant parts were ground into powder, 
mixed with water or sesame oil and used as mouthwash or ointment, and juice 
from leaves and stem topically applied) for 31 plant species; infusions taken 
orally/water decoctions for 20 species; or both topical and water decoctions for 5 
species. The commonest plant parts mentioned to be used were leaves (30%), 
followed by roots (29%) and the least used were tubers and fruits (3% each). 
Analysis of the data based on their habits showed that 21 species (37%) were 
trees, 18 species (32%) were shrubs, 11 species (20%) were herbs and 6 
species (11%) were climbers. Adverse effects were only reported for three 
species; Euphorbia tirucali L. juice from leaves may cause blindness when in 
contact with eyes, and bitter and sour taste for Rhoicissus tridentata (Fresm) 
Placium and Cucumis aculeatus Cogn, respectively. Literature reports (Table 2) 
showed that 15 (27%) plant species have reports of similar ethnomedical uses or 
proven in vitro antifungal activity. Two plants Euphorbia heterophylla (Rocha e 
Silva, 1943) and Jatropha multifida were reported to be toxic (Levin et al., 
2000).  
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Table 1  
Herbal plants reported to be used by traditional healers for treatment of fungal infections in Tanzania  
Family Species (Voucher Specimen No.) Local name Part useda Life form Preparation Other usesb 
ALOACEAE Aloe lateritia Engl.  (OH 10) Mapunisinyamviri WP Shrub Topical Snake poison 
              
ANACARDIACEAE Lannea stuhlmanii Engl. (OH 7) Muhungilo L Tree Topical b 
  Sclerocariya birrea Sond (OH 8) Muongozi L, R Tree Topical Snake poison 
ANNONACEAE Annona senegalensis Purs. (OH 11) Mnene kanda L, R Shrub Topical (L), 
Hernia, 
asthma 
          Oral (R)   
APOCYNACEAE 
Strophanthus eminii Asch & Pax (OH 
25) Muhunguti RB Shrub Oral  b 
              
ARACEAE Gonatopus boivinii Hook.f. (OH 1) Kunzulu T Herb Topical Swellings 
              
BALANITACEAE Balanites aegyptiaca (L.) Del (OH 17) Mudughuyu RB Tree Topical b 
              
BIGNONIACEAE Kigelia africana L. (OH 49) Mungungu RB, F Tree Oral b 
              
BORAGINACEAE Cordia africana Lam (OH 9) Mgwengweni R Shrub Topical b 
              
BURSARACEAE Commiphora pteleifolia Engl. (OH 34) Twini ndedemu R Shrub Topical b 
              
CAMPANULACEAE Lobelia giberroa Neumeleg (OH 35) Gongoa L Herb Topical b 
              
CAESAEPINACEAE Cassia abbreviata Oliv. (OH 20) Mufafati R, SB Tree Oral b 
  Cassia singuena Del (OH 12) Muhufia  R Shrub Topical / Oral 
Hernia, skin 
rashes 
              
CARYOPHYLLACEAE 
Drymaria cordata (L) A.Schult (OH 
46) Ugurashishi WP Herb Topical b 
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Table 1  
Herbal plants reported to be used by traditional healers for treatment of fungal infections in Tanzania  
              
CELASTRACEAE 
Elaeodendron buchananii (Loes)(OH 
19) Muhorachwi SB Tree Oral Pmeumonia 
Family Species (Voucher Specimen No.) Local name Part useda Life form Preparation Other usesb 
  Elaeodendron schlechteranum   Mkandekande SB Tree Oral Herpes zoster 
  (Loes) (OH 50)           
COMPOSITAE Tagetes minuta  L. (OH 43) Mbangi L Climber Topical * 
              
CRUCIFERAE Coronopus didymus (L) (OH 47) Kissango WP Herb Oral Haermorhoids 
              
CUCURBITACEAE Cucumis aculeatus Cogn. (OH 32) Ingángáa F Climber Topical * 
  Senecio deltoidea Less (OH 33) Ulenge WP Climber Oral * 
  Zehneria scabra (L.f) Sond   (OH 42) Foiza WP Climber Topical Dermatitis 
              
DENNSSTRAEDIACEAE 
Pteridium aquilinum (L.) Kuhn (OH 
41) Shilu  L Herb Topical * 
              
EBENACEAE Diospyros usambarensis F.  (OH 26) Muriorio R Shrub Topical * 
              
ERICACEAE Agauria salicifolia Oliv. (OH 45) Mwomboa L Tree Topical * 
              
EUPHORBIACEAE Acalypha fruticosa Forsk.  (OH 56) Siaiti L, R Shrub Topical (L),  * 
     Oral (R)  
  Croton Scheffleri Pax  (OH 24) Muhalange  R Shrub Oral  * 
  Euphorbia tirucali L.  (OH 57) Injokii L Tree Topical * 
  Euphorbia heterophylla L. (OH 31) Loo WP Herb Oral * 
  Jatropha multifida L. (OH 53) Maugwamwipoli L,S,R Shrub Topical * 
  
Spirostachys africana Sonder (OH 
54) Ormotanga S Tree Topical * 
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Table 1  
Herbal plants reported to be used by traditional healers for treatment of fungal infections in Tanzania  
              
GUTTEFERAE  
Hypericum roeperanum A. Rich (OH 
44) Mwambaziwa  L Shrub Topical * 
              
LABIATAE Ocimum basilicum L. (OH 29) Irumbasi WP Herb Oral * 
  Ocimum suave Oliv. (OH 13) Suameno L Herb Topical 
Roots used 
for hernia 
Family Species (Voucher Specimen No.) Local name Part useda Life form Preparation Other usesb 
LOGANIACEAE Strychnos potatorum Gilg. (OH 21) Mumpande L Tree Oral 
Pain, 
asthma,lack 
of appetite 
              
MELIACEAE Turraea holstii Gurk  (OH 37) Muhenga L Shrub Oral Convulsions 
  Khaya anthotheca C.Dc (OH 52) Mgolaminzi SB Tree Topical * 
              
MIMOSACEAE 
Albizia anthelmintica (A. Rich) Brogn 
(OH 3) Mfuleta R Tree Oral 
Worms, 
asthma 
              
  Acacia robusta subsp Usambarensis  Mkame L Tree Topical Convulsions 
  (Taub) Brenan (OH 38)          
  
Acacia nilotica (L.) Willd ex Del (OH 
58) Kloriti S Shrub Topical * 
              
MORACEAE Ficus sur. Benth (OH 51) Mkuyu SB Tree Oral/Topical * 
              
MYRSINACEAE 
Rapanea melanophloeus (L.) Mez 
(OH 5) Mpaja L, SB Tree Oral  * 
              
PAPILIONACEAE 
Indigofera rhynchocarpa Bak. Var  
(OH 16) Igangula R Shrub Topical Syphillis 
  Erythrina abyssinica Lam (OH 18) Mkalalwanhuwa R Tree Topical Worms 
              
POLYGONACEAE 
Securidaca longipedunculata Fres 
(OH 28) Musatu R Shrub Oral * 
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Table 1  
Herbal plants reported to be used by traditional healers for treatment of fungal infections in Tanzania  
PLUMBAGINACEAE Plymbago zeylannica L. (OH 36) Chambula R Herb Oral * 
              
RHAMNACEAE Ziziphus pubercens Oliv. (OH 55) Indigrishi L Shrub Topical  * 
              
RUTACEAE Clausena anisata Oliv (OH 6) Mjavikali L,SB,R Shrub Oral 
Convulsions, 
gonnorhea 
  Zanthoxylum chalybeum L. (OH 22) Mulungu RB Tree Topical/Oral Cough 
             
RUBIACEAE 
Hymenidictyon parvifolium Brig (OH 
2) Pekawake R Shrub Topical * 
SALVADORACEAE Salvadora persica L (OH 30) Mukunkuni R Tree Topical Gonnorhea 
              
STERCULIACEAE 
Sterculia africana (Lour) Fiori (OH 
39) Muhoza L Tree Oral Convulsions 
              
SAPOTACEAE 
Chrysophyllum bangweolense RE Fris 
(OH 15) Mseweye RB Tree Topical * 
              
SOLANACEAE Solanum incanum L (OH 23) Mtula ndulele WP Herb Oral * 
              
VITACEAE 
Rhoicissus tridentata (Fresm) 
Placium 
(OH 27) Iforiyo T Climber Oral * 
  Cissus petiolata Hook. F. (OH 48) Mswilaswila R Climber Topical 
Edema of the 
legs 
  
Cyphostemma hildebrandtii (Gilg) 
Desc. (OH 14) Damanyamwili L Herb Topical * 
      
 
a F, Fruit; L, Leaves; R, Roots; RB, Root bark; S, Stem; SB, Stem bark; T, Tubor; WP,whole plant. 
b No other uses reported. 
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Table 2.  Reports from the literature showing similar ethnomedical claims and proven laboratory results showing antifungal  
activity for some of the plants reported by Tanzanian traditional healers         
 
Plant name Literature reports of related ethnomedical uses and proven antifungal activity 
  Acacia nilotica  Different extracts of the plant have been reported to have antifungal activity against yeasts and other fungi 
(Gupta and Bilgrami, 1970; Nabi et al., 1992; Sinha and Anjana, 1984; Srinivasan et al., 2001; Ahmad et al., 
1998; Almagboul et al., 1988; Srivastava et al., 1984).   
 
 Acalypha fruticosa Cold-water extract of fresh leaves is used for skin disease; patient is bathed with cold-water extract, or 
smoke from burning dry leaves is inhaled.  It is used in combination with Zanthoxylum chalybeum and 
Suregada zanzibariensis (Hedberg et al., 1983a). Acetone, chloroform and hexane extracts of exhibited 
antifungal activity against C. albicans (Alasbahi et al., 1999). 
 
Balanites aegyptiaca Ethanol extract exhibited antifungal activity against Penicillium crustosum, Saccharomyces cerevisiae 
(Taniguchi et al., 1978; Liu and Nakanishi, 1982), and the saponin fraction showed antifungal activity against 
Aedes aegypti, A.niger and C. albicans (Saeed et al., 1995) 
 
Clausena anisata 
 
Decoction is used orally to treat mouth infections (Adesina and Adewunmi, 1985).  A 50% aqueous ethanol 
extract exhibited antifungal activity against A.niger, Microsporum canis, and Trichophyton mentagrophytes 
(Aswal et al., 1984). Clausenol, carbazole alkaloid isolated from alcoholic extracts exhibited antifungal activity 
against C.albicans (Chakraborty et al., 1995). 
Diospyros usambarensis Used as chewing stick (Khan et al., 2000)  
Drymaria cordata  Plant juice of the leaves is used externally for skin diseases (Rao, 1981; Saklani and Jain, 1989). 
Erythrina abbyssinica Infusions of the bark three times a day per oral reported for treatment of candidiasis. (Hamil et al., 2000). S.  
cerevisiae, P. crustosum (Taniguchi et al., 1978; Kamat et al., 1981; Taniguchi and Kubo, 1993). 
 
Euphorbia heterophylla  Reported to be toxic (Rocha e Silva, 1943). 
Hymenodictyon parvifolium A methanol extract exhibited antifungal activity against C. albicans, T. mentagrophytes and M. gypseum 
(Kariba, 2002). 
Jatropha multifida Reported to cause toxicity to two children (Levin et al., 2000) 
 
Ocimum basilicum Essential oil reported to have antifungal activity against T. mentagrophytes, M. gypseum, T. rubrum (Dikshit 
et al., 1984), Yeast (Ela et al., 1996), P. digitatum (Arora and Pandey, 1984) and A. niger. (Meena and Sethi, 
1994). 
 
Rhoicissus tridentate Methanol extract exhibited antifungal activity against C. albicans and S. sereviciae. (Lin et al., 1999). 
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Table 2 (Continued) 
Salvadora persica It is used as toothbrush (Johns et al., 1996; Al-said, 1993); dentrifice (Farooqi and Srivastava, 1968); 
Chewing stick (Hattab, 1997); and has anti-ulcer activity (Islam et al., 2000; Monforte et al., 2001). The 
plant exhibited weak anti yeast activity (Chhabra et al., 1991). 
 
Sclerocarya birrea  Stem bark ethanol extracts exhibited strong activity against C. albicans. (Adoum et al., 1997). 
 
Solanum incanum Used for skin diseases and treatment of ringworm (Herdberg et al., 1983b; Sawhney et al., 1978); Methanol 
extract exhibited antifungal activity against C. albicans (Sawhney et al., 1978; Al-Yahya et al., 1983) and T. 
mentagrophytes (Sawhney et al., 1978). 
 
Securidaca longipedunculata Root bark extracts exhibited antifungal activity against S. sereviciae. (Taniguchi et al., 1978). 
Tagetes minuta Used for treatment of ringworm infections (Bii et al., 2000); Oil from flowers and leaves exhibited antifungal 
activity against C. albicans, C. neoformans, T. metangrophytes and M. gypsum (Bii et al., 2000); Ethanol 
extracts of leaves exhibited activity against C.albicans. (Motsei et al., 2003); 
Zanthoxylum chalybeum Used for skin diseases. Leaves of Acalypha fruticosa, Zanthoxylum chalybeum and Suregada zanzibariensis 
are pounded together and juice is applied to affected area (Hedberg et al., 1983a; Chhabra et al., 1991); 
 Exhibited antifungal activity against P. crustosum and S. cerevisiae (Taniguchi et al., 1978). 
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3.2 Antifungal activity 
Among the 65 plant extracts tested 26 (40%) extracts, belonging to 25 (45%) 
plant species, completely inhibited the growth of one or more of the tested fungi. 
Table 3 shows the MICs and MFCs of the active methanol plant extracts. The 
most susceptible yeasts based on the high number of active plant extracts 
inhibiting its growth were Cryptococcus neoformans followed by Candida krusei, 
Candida tropicalis and Candida parapsilosis. Out of 26 active plant extracts, 21 
(80%) showed activity against Cryptococcus neoformans, 17 (65%), 16 (61.5%), 
11 (42%) and 5 (19%) against Candida krusei, Candida tropicalis, Candida 
parapsilosis and Candida glabrata, respectively.  Candida albicans was the least 
susceptible of all the yeasts. Only 4 (15%) of the plant extracts, including 
Clausena anisata Oliv., Sclerocariya birrea Sond, Turraea holstii Gurk, and 
Spirotachys africana Sonder inhibited its growth. The extracts that exhibited the 
broadest spectra of antifungal activity (activity against at least four yeasts) were 
Clausena anisata Oliv., Agauria salicifolia Oliv., Sclerocariya birrea Sond, Acacia 
robusta subsp. Usambarensis (Taub) Brenan, Cyphosterma  hildebrandtii (Gilg) 
Desc, Turraea holstii Gurk, Sterculia africana (Lour) Fiori, Zanthoxylum 
chalybeum L. and Acacia nilotica (L.) Willd ex Del.  
 
There are no validated criteria for the MIC end points for in vitro testing of plant 
extracts, however, Aligiannis et al. (2001) proposed classification for plant 
materials, based on MIC results as follows: Strong inhibitors – MIC up to 0.5 
mg/ml; moderate inhibitors – MIC between 0.6 and 1.5 mg/ml and weak 
inhibitors – MIC above 1.6 mg/ml. In our study we tested up to maximum 
concentration of 4 mg/ml. Based on the above classification Clausena anisata 
Oliv. stem bark, Sclerocariya birrea Sond, Turraea holstii Gurk leaves, Sterculia 
africana (Lour) Fiori, Acacia robusta subsp. Usambarensis (Taub) Brenan, 
Cyphosterma hildebrandti (Gilg) Desc, Elaeodendron buchannanii (Lows) leaves, 
Acacia nilotica (L.) Wild ex Del stem, Agauria salicifolia, Jatropha multifida L., 
Pteridyum aquillinum showed strong activity to one or more tested 
microorganisms. This study shows that information obtained from traditional 
healers can lead to discovery of therapeutically useful agents. From the 56 plant 
species which were reported by the healers only 2 (3.6%) plants, Euphorbia 
heterophylla (Rocha e Silva, 1943) and Jatropha multifida (Levin et al., 2000) 
had previous literature reports of toxicity, while 14 plant species had previous 
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reports of confirmed in vitro antifungal activity. Among the 14 plant species 
previously reported to have in vitro antifungal activity the results were confirmed 
in the present study for 8 species; Acacia nilotica, Hymenodictyon parvifolium, 
Clausena anisata, Rhoicissus tridentate, Solanum incanum, Sclerocariya birrea, 
Tagetes minuta and Zanthoxylum chalybeum (Gupta and Bilgrami, 1970; 
Sawhney et al., 1978; Chhabra et al., 1982; Aswal et al., 1984; Sinha and 
Anjana, 1984; Srivastava et al., 1984; Almagboul et al., 1988; Abd el Nabi et al., 
1992; Chakraborty et al., 1995; Ahmad et al., 1998; Srinivasan et al., 2001; 
Motsei and Lindsey, 2003) . The antifungal activity for the above plants were 
previously determined by other methods except for Tagetes minuta (Motsei and 
Lindsey, 2003), which similar to our study used a broth microdilution method 
(NCCLS, 2002).    
 
 The detection of antifungal activity in nearly 50% of the plant species gives the 
claims by traditional healers a significantly high credibility.  However, 31 plant 
species (39 extracts) did not show activity against any of the test 
microorganisms. In contrast to previous reports several plant extracts did not 
exhibit in vitro antifungal activity including Salvadora persica L., Securidaca 
longipedunculata, Acalypha fruticosa, Balanites aegyptiaca, Erythrina abbyssinica 
and Ocimum basilicum (Taniguchi et al., 1978; Taniguchi and Kubo, 1993; Al-
Bagieh et al., 1994; Meena and Sethi, 1994; Saeed et al., 1995; Ela et al., 1996; 
Alasbahi et al., 1999). This was also the case for infusions of the bark of 
Erythrina abbyssinica three times a day orally indicated for treatment of 
candidiasis (Hamil et al., 2000).  Besides the absence of active compounds other 
reasons could explain the lack of antifungal activity, including the parts of the 
plants used, the solvent used for extraction, the location where the plants were 
collected, and possibly the time of collection.  
 
Agauria salicifolia Oliv. leaves showed activity against all yeasts except Candida 
albicans. The leaves also showed fungicidal activity against Candida glabrata. 
Little is known regarding the antifungal activity and compounds from leaves of 
Agauria salicifolia Oliv.  Sclerocariya birrea Sond roots showed fungistatic activity 
against all yeasts except Candida glabrata.  Extracts from leaves of Acacia 
robusta subsp. Usambarensis (Taub) Brenan and Cyphosterma hildebrandti (Gilg) 
Desc showed fungistatic activity against all yeasts except Candida albicans, while 
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extracts from leaves of Turraea holstii Gurk was active against all yeasts except 
Candida glabrata. Extracts from leaves of Sterculia africana (Lour) Fiori and stem 
of Jatropha multifida L. have shown activity on the yeasts except Candida 
albicans and Candida glabrata. Extracts from the stem of Spirostachys africana 
Sonder showed fungicidal activity against Candida albicans and Candida glabrata, 
the yeasts that showed the least susceptibility of all the tested yeasts in this 
study. Little is known from the literature regarding antifungal activity and the 
active compounds from roots of Sclerocarya birrea Sond, stems of Jatropha 
multifida L. and Spirostachys africana Sonder, leaves of Acacia robusta subsp. 
Usambarensis (Taub) Brenan, Cyphosterma hildebrandti (Gilg) Desc, 
Elaeodendron buchannanii (Lows) and Sterculia africana (Lour). Further research 
is warranted to identify their active compounds. 
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Table 3: In vitro activity of plant extracts against selected yeast and mould isolates 
 
Botanical name:  Species Plant 
parta 
C.ab C.g C.p C.t C.k Cr.n 
  MIC0/MFC
c MIC0/MFC MIC0/MFC MIC0/MFC MIC0/MFC MIC0/MFC 
Acacia robusta subsp 
Usambarensis (Taub) Brenan L 
-/-        1000/- 63/- 500/1000 31/- 4000/- 
Acacia nilotica (L) Willd ex 
Del. SB 
-/-  -/-  31/- 63/- 1000/1000 4000/- 
Agauria salicifolia Oliv. L -/-  500/4000 1000/- 4000/- 2000/- 1000/- 
Clausena anisata Oliv SB 
1000/1000 4000/- 63/125 125/250 250/500 250/250 
Cyphostemma hildebrandtii 
(Gilg) Desc L 
-/- 1000/- 1000/- 250/500 1000/- 500/- 
Drymaria cordata (L) A. 
Schult WP 
 -/- -/-  -/- -/- 4000/4000 -/- 
Elaeodendron schlechteranum 
(Loes) SB 
 -/- -/-  -/-  -/- 200/- 250/- 
Elaeodendron buchannanii 
(Loes) SB 
 -/- -/-     -/- 250/- 63/- 31/- 
Euphorbia heterophylla L. WP 
 -/- -/-   -/- 4000/400
0 
-/- 4000/- 
Hymenidictyon parvifolium 
Brig. R 
 
 -/- 
 
-/- 
 
 -/- 
 
-/- 
 
 -/- 
 
125/- 
Jatropha multifida L. S  -/- -/-  1000/- 250/250  -/- 1000/- 
Jatropha multifida L. R  -/- -/-   -/- -/-  -/- 4000/- 
Khaya anthotheca C.Dc. SB  -/- -/-   -/- -/- 200/- -/- 
Kigelia africana L. F  -/- -/-  -/- -/- -/- 1000/- 
Pteridium aquilinum (L.) Kuhn  L 
 -/- -/-    -/- 500/- 500/- -/- 
Rapanea melanophloeus (L.) 
Mez.  SB 
 -/- -/-   -/- -/- 1000/- 500/- 
Rhoicissus tridentata (Fresm) 
Placium. T 
 -/- -/-   -/- -/- 125/- -/- 
Sclerocarya birrea Sond R 250/- -/- 125/- 63/- 63/- 250/- 
Senecio deltoidea Less WP  -/- -/-  -/- 250/500  -/- -/- 
Solanum incanum L.  L  -/- -/-  4000/- 4000/- -/-  -/- 
Sterculia africana (Lour) Fiori. L -/- -/-   1000/- 63/500 250/- 1000/1000 
Spirostachys africana Sonder  
S 
2000/2000 1000/200
0 
 -/-   -/-    -/-  1000/- 
Tagetes minuta L. L  -/- -/- -/- 500/- 1000/- 500/- 
Turraea holstii Gurk 
 L 
500/- -/- 1000/- 63/500 500/- 125/- 
Zanthoxylum chalybeum L. RB 
 -/-  -/- 2000/- 2000/400
0 
2000/2000  2000/- 
Ziziphus pubercens Oliv.  L  -/-  -/-   -/- -/- 1000/- 4000/- 
 
MFC, Minimum Fungicidal Concentration (µg/ml);  -, No in vitro activity at concentration equal 
or less than 4000 µg/ml.    
aF, Fruits; L, leaves; R, Root; RT, Root Bark; S, Stem; SB, Stem bark; T, Tuber; WP, Whole 
plant.bC.a, Candida albicans; C.g, Candida glabrata; C.p, Candida parapsilosis; C.t, Candida 
tropicalis; C.k, Candida krusei; Cr.n, Cryptococcus neoformans. 
cMIC0, Concentration (µg/ml) that visually showed no growth and percentage growth less than 
5% spectrophotometrically. 
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4.  Conclusions 
Results of the present study suggest a fairly good correlation between traditional 
therapeutic use and the in vitro antifungal activity. These results corroborate the 
importance of ethnobotanical surveys for screening plants as a potential source 
for bioactive compounds. Hence these could result in discovery of novel 
antifungal agents.  Further bio-guided fractionation will be conducted for roots of 
Sclerocarya birrea Sond, leaves of Acacia robusta subsp. Usambarensis (Taub) 
Brenan, Turraea holstii Gurk, Agauria salicifolia, Sterculia africana (Lour) Fiori, 
Cyphosterma hildebrandtii (Gilg), Elaeodendron buchannanii (Lows) and stem of 
Spirostachys africana Sonder to identify the active compounds. 
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Abstract 
Background. Oropharyngeal candidiasis is the most common opportunistic 
infection affecting patients with human immunodeficiency virus (HIV) infection. 
Because of convenience, cost, and reluctance to complicate antiretroviral 
treatment regimens, single-dose fluconazole may be a favourable regimen for 
treatment of moderate to severe oropharyngeal candidiasis. We conducted a 
prospective, randomized, double-blind, double-dummy trial to compare the 
clinical and mycological responses, relapse rates, and safety of a single 750-mg 
dose and a 14-day course of treatment with fluconazole.  
Methods. A total of 220 HIV-infected patients with clinical and mycological 
evidence of oropharyngeal candidiasis were randomly assigned in a 1:1 ratio to 
receive either a 750-mg single dose of orally administered fluconazole (110 
patients) or 150 mg of orally administered fluconazole once per day for 2 weeks 
(110 patients). The primary efficacy analysis was based on clinical and 
mycological responses at the end of treatment. Secondary parameters were 
safety and relapse rate. 
Results. Single-dose fluconazole was equivalent to a 14-day course fluconazole 
in achieving clinical and mycological cure, with a clinical cure rates of 94.5% and 
95.5%, respectively (odds ratio, 0.825; 95% confidence interval, 0.244 - 2.789; 
P = 0.99), and mycological cure rates of 84.5% and 75.5%, respectively (odds 
ratio, 1.780; 95% confidence interval, 0.906-3.496; P = 0.129). Drug-related 
adverse events were uncommon and were not different between the treatment 
groups.  
Conclusion. A single dose of 750 mg of fluconazole was safe, well tolerated, and 
as effective as the standard 14-day fluconazole therapy in patients with HIV 
infection and acquired immunodeficiency syndrome who had oropharyngeal 
candidiasis coinfection. 
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Introduction 
Oropharyngeal candidiasis (OPC) has been reported to occur in up to 90% of 
subjects infected with human immunodeficiency virus (HIV); therefore, OPC is 
the most commonly encountered opportunistic infection in these patients (1,2). 
As a result of highly active antiretroviral therapy (HAART), the incidence and 
prevalence of most opportunistic infections has greatly decreased (3,4). 
However, OPC remains the most frequent HIV-associated oral disease in sub-
Saharan Africa, where access to HAART is still limited (5,6). The occurrence of 
OPC is associated with low CD4 T-lymphocyte numbers, high viral loads and 
disease progression (1,4,7), but at the same time, OPC tends to be one of the 
first opportunistic infections seen in patients with CD4 T-lymphocyte levels <200 
cells/mm3.  
 
In Tanzania, fluconazole, at a dose of 150 mg once per day for 2 weeks, is 
included in the guidelines for the treatment of OPC in HIV-infected patients (8). 
Treatment with fluconazole achieved complete clinical response in 87%–100% of 
patients and was effective in obtaining a mycological cure in 53%–87% of 
patients after a 7, 14, or 28-day course of therapy (9–14). Single-dose 
fluconazole (150 mg) therapy has been reported to lead to complete clinical 
response in 75%–100% of patients and mycological eradication of Candida 
species in 6%–41%, whereas 30%–38.5% of patients experienced relapse during 
follow-up after treatment (15–17). However, the single-dose fluconazole studies 
involved a limited number of patients, may have been performed with a 
suboptimal fluconazole dose, and did not make use of a randomized study 
design. Because of convenience, cost and reluctance to complicate antiretroviral 
treatment regimens, single-dose fluconazole may be a more favorable regimen 
for treatment of HIV-associated OPC than the recommended dose of 150 mg of 
fluconazole once per day, administered orally, for 2 weeks (8). 
 
The aim of our study was to determine whether a single dose of 750 mg of 
fluconazole was as effective as the standard 14-day course of fluconazole for the 
treatment of OPC in HIV-infected patients. 
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Patients and Methods 
Patients  
Participants were recruited at the HIV clinic of the Muhimbili National Hospital 
(Dar es Salaam, Tanzania) from November 2006 through December 2007. 
Patients were eligible for the study if they met the following criteria: ≥18 years 
of age, with documented HIV infection (as determined by positive ELISA results 
and confirmed by Western blot analysis); clinical symptoms of OPC; 
characteristic visual lesions; and microbiological confirmation.   
Patients were excluded from study participation for any of the following reasons: 
ongoing or previous topical or systemic antifungal therapy within 3 days before 
study enrollment; a history of allergy to azole derivatives; abnormal results of 
liver function tests, defined as alanine aminotransferase (ALT), aspartate 
aminotransferases (AST), or direct or total bilirubin levels >3 times the upper 
limit of normal; evidence of significant hepatic or renal disease within 2 months 
before study enrollment; inability to tolerate oral drug administration; current 
pregnancy or breast feeding; life expectancy of <4 weeks; current participation 
in another clinical trial; current treatment with drugs that are known to interact 
with fluconazole; documented systemic fungal infections; and symptoms 
suggestive of esophageal candidiasis. Also, patients with a history of alcohol 
abuse, drug addiction, psychiatric disorders, inability to cooperate, and poor 
motivation were excluded from the study.  
The study was performed in accordance with good clinical practices and the 
principles set forth in the World Medical Assembly Declaration of Helsinki. The 
Ethics Committee of the Muhimbili University of Health and Allied Sciences and 
Muhimbili National Hospital approved the study protocol, and each patient signed 
a written statement of informed consent before enrollment and receipt of study 
medication.   
 
Study Design and Procedures 
We conducted a prospective, randomized, double blind, double-dummy trial to 
compare the clinical and mycological responses, relapse rates, and safety of 2 
regimens of fluconazole therapy for treatment of OPC in HIV-infected patients. 
Eligible patients were randomized in a 1:1 ratio to 1 of the 2 treatment groups on 
the basis of a predefined randomization code. The pharmacist, who dispensed the 
medicine, held the randomization code, and neither the evaluator nor the 
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patients had knowledge of what treatment was given. Patients were randomized 
to receive oral treatment of a single dose of 750 mg (5 tablets of 150 mg) of 
fluconazole and 1 placebo tablet once per day for 2 weeks or a standard regimen 
of orally administered fluconazole (1 tablet of 150 mg) once per day for 2 weeks 
(8). These patients also received 5 placebo tablets on the first day of therapy. 
After the baseline visit on day 0, visits were scheduled for day 3 or 4, day 6 or 7, 
day 14 (end of therapy), and day 42 (follow-up). At baseline, a structured 
standard questionnaire was used to systematically collect demographic 
information, medical history, treatment history, concomitant illness(es), and 
current treatments. General and oral examinations were performed at baseline 
and at subsequent visits, with use of a standard oral examination method (18). 
On days 3 or 4, 6 or 7 and 14, patients were examined and assessed for signs 
and symptoms, adverse drug effects, and compliance with the regimen. Clinical 
adverse effects were recorded at each visit and were graded as mild, moderate, 
or severe. Patients were asked to bring the remaining study medication during 
follow-up visits, and pill count was performed by a pharmacist and the result was 
recorded.  Follow-up examinations in both treatment groups were performed on 
day 42 or earlier if patients experienced relapse. A single examiner evaluated all 
patients throughout the trial. 
 
Oral swab specimens were obtained at baseline for diagnosis, and on day 14 for 
mycological evaluation, and on day 42 or earlier when there was evidence of a 
relapse of OPC. Specimens were obtained by firmly swabbing the lesion site with 
a sterile cotton wool swab (19). The swabs were sent immediately to the 
laboratory for microbiological confirmation. Isolates were identified to the species 
level, and antifungal susceptibility to fluconazole was assessed according to the 
guidelines of the Clinical and Laboratory Standards Institute (CLSI) (20). 
 
Blood samples were obtained at baseline for determination of basic hematology, 
for biochemical tests, and to assess CD4 and CD8 cell counts. Blood samples 
were also obtained at the end of the treatment (day 14) for hematology and 
biochemical tests.  Also, blood samples from 25 randomly selected patients (13 
patients receiving a single-dose and 12 receiving standard therapy) were 
obtained at baseline, on day 1, on day 4 or 5, on day 7, and on day 14, for 
determination of fluconazole plasma concentrations. Fluconazole plasma 
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concentrations were measured by means of protein precipitation followed by a 
tandem-mass spectrometric detection, with use of internal standard and spiked-
pool serum samples as controls.  
 
Efficacy evaluations 
The efficacy of each of the 2 treatment regimens was assessed by comparison of 
primary outcome measures that included clinical and mycological responses at 
the end of treatment. The severity of signs and symptoms at baseline and at end 
of therapy and the extent of lesions were graded and scored. Lesions were 
monitored with assistance of oral-cavity diagrams for estimating lesion sizes and 
locations. The overall OPC clinical score based on signs, symptoms, and extent of 
lesions were graded as absent (no symptoms or lesions present), mild 
(scattered, nonconfluent lesions > 2 mm in size), moderate (multiple lesions > 2 
mm in size), and severe (extensive, confluent lesions). Clinical responses were 
defined as cured (complete resolution of lesions, signs, and symptoms of OPC), 
improved (a reduction in the number of lesions and symptoms but persisting 
typical oropharyngeal lesion), or failed (no resolution of signs and symptoms; 
i.e., either no change or OPC that has progressed). In evaluation of results of 
mycological cultures on day 14, any growth of Candida species was classified as 
mycological treatment failure. 
  
Secondary outcome measures included relapse of OPC and safety of the 2 
fluconazole regimens. Relapse was defined as an initial cure followed by 
reappearance of symptoms, clinical signs of OPC, and/or confirmation by positive 
yeast culture during a follow-up period of 4 weeks after the end of treatment. 
Patients with a clinical evaluation of “cured” on day 14 were considered to have a 
successful outcome and were eligible for the follow-up phase.  
 
Safety evaluations 
Safety and tolerability were assessed by the observation of adverse events. 
Baseline and posttreatment blood investigations included biochemical tests and 
full blood count and were compared between the 2 regimens.  
 
 
 
 99 
Statistical Analysis 
This trial was designed to have 80% power to demonstrate equivalence (within 
20%) in clinical response between the 2 fluconazole regimens, and the 95% 
confidence intervals (CI) of the difference in response rates were used in 
determination of equivalence. Data were analyzed using the SPSS, version 14.0. 
Comparisons between the 2 treatment groups were performed using Student’s t-
test whenever continuous variables were normally distributed; for skewed 
distributions, the Mann-Whitney U test was used. Noncontinuous categorical and 
ordinal variables were analyzed using Fisher’s exact test. The results of 
posttreatment liver function test and full blood count were compared (between 
the 2 fluconazole regimens) by analysis of covariance, with the pretreatment test 
result as a co-variate. All statistical tests were two-tailed and exact probabilities 
were reported in each test. 
 
Results 
Demographic baseline and clinical characteristics  
A total of 220 patients were randomized to either the single-dose fluconazole 
group (110 patients) or the 14-day fluconazole group (110 patients). The 
baseline clinical and demographic characteristics were similar in both treatment 
groups (table 1). The median CD4 cell count, World Health Organization HIV 
clinical stage, and OPC clinical score were similar in all treatment groups. More 
than one-half of patients in both treatment groups were not receiving 
antiretroviral therapy at baseline. Eighty (36.4%) of 220 patients were receiving 
HAART, which comprised combinations as followa: stavudine, lamivudine, and 
nevirapine in 57 patients (71.3%); zidovudine, lamivudine, and efavirenz in 20 
patients (25%); and zidovudine, lamivudine, and nevirapine in 2 patients 
(2.5%). One patient (1.3%) was receiving stavudine, didanosine, and ritonavir-
lopinavir. More than one-half of the patients (40 patients; 55%) had received 
HAART for <3 months. With regard to previous exposure to azole antifungal 
agents, the proportions were also equal between the 2 treatment groups. As 
measured by the pill counts, all 220 patients were highly compliant with the 
study treatment regimens. 
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Baseline Mycological findings and Susceptibility Testing 
Candida albicans comprised 90% of pretreatment isolates, and there were no 
statistically significant differences in species distribution and minimum inhibitory 
concentrations (MICs) of fluconazole between the treatment groups at baseline 
(P = 0.823). 
 Table 1. Patient Demographics and Baseline Characteristics 
    Treatment group 
   Fluconazole   Fluconazole Total  P-valuea 
 Test 
 Variable 14 days (n=110) SDo (n=110)(n=220) 
 
Gender n (%) 
 Male   27 (24.5) 26 (23.6) 53 (24.1) 1.000  F 
 Female  83 (75.5) 84 (76.4) 167 (75.9)  
Age (yrs) 
 Mean±SD  35±8.1 34±7.9 34.8±8.0 0.130  t 
 Range   22-75  19-63  19-75 
Body Mass Index 
 Mean±SD  20.9±4.0 21.0±3.3 20.9±3.7 0.908  t 
 Range   13.1-38.1 13.6-32.4 13.1-38.1  
CD4 count/mm3 
 Median  100  88  100  0.578  MW 
 Range   3-689  2-614  2-689   
WHO stage n (%) 
 III   86 (78.2) 94 (85.5) 180 (81.8) 0.221  F 
 IV   24 (21.8) 16 (14.5) 40 (18.2) 
OPC clinical score n (%) 
 Mild   6 (5.5) 4 (3.6) 10 (4.5) 0.835  F 
 Moderate  73 (66.4) 76 (69.1) 149 (67.7) 
 Severe  31 (28.2) 30 (27.3) 61 (27.7) 
History of OPC n (%) 
 Primary  66 (60) 64 (58.2) 130 (59.1) 0.891  F 
 Recurrent  44 (40) 46 (41.8) 90 (40.9) 
Pretreatment isolates 
n (%) 
 C.albicans  100 (90.9) 98 (89.1) 198 (90.0) 0.823  F 
 C.krusei  4     (3.6) 2   (1.8) 6     (2.7) 
 C.glabrata  2     (1.8) 3   (2.7) 5     (2.3) 
 C.tropicalis  1     (0.9) 4   (3.6) 5     (2.3) 
 C.kefyr  2     (1.8) -  2     (0.9) 
 C.albicans &C.krusei -  2   (1.8) 2     (0.9) 
 C.glabrata&C.krusei 1     (0.9) 1   (0.9) 2     (0.9) 
 
Prior azoles antifungal 
 exposure n (%)  56 (50.9) 56 (50.9) 112 (50.9) 1.000  F 
 
Use of HAART n (%) 
 Yes   39 (35.5) 41 (37.3) 80 (36.4) 0.889  F 
 No   71 (64.5) 69 (62.7) 140 (63.6) 
 
SDo, single-dose; SD, standard deviation; F, Fisher’s exact test; t, t-test; MW, Mann-
Whitney U-test. aFluconazole 14-days course compared to fluconazole single-dose. 
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Efficacy Analysis 
All 220 enrolled patients were evaluable for clinical and mycological responses.  
Clinical efficacy. In the 14-day fluconazole group, 105 patients (95.5%) were 
considered to be clinically cured, 4 patients (3.6%) had improved clinically, and 1 
(0.9%) experienced treatment failure. In the single-dose fluconazole group, 104 
patients (94.5%) were considered to be clinically cured, 2 patients (1.8%) had 
improved clinically, and 4 patients (3.6%) experienced treatment failure. The 
difference in clinical success between the 2 treatment groups was not significant 
(OR, 0.825; 95% CI, 0.244 - 2.789; P = 0.99). There was a significant 
association between higher MICs for fluconazole at baseline and poor clinical 
outcome (P = 0.016). There were no significant associations between clinical 
outcome and CD4 cell count and previous azole exposure (P = 0.089 and P = 
0.805, respectively). Ninety patients with recurrent OPC at baseline (72.2%) had 
a history of 1 previous episode of OPC, and the range of recurrences was 1–4 
episodes. There were no statistically significant associations between clinical 
outcome and number of previous OPC episodes.  
 
Mycological efficacy. At baseline, all enrolled patients had positive results on 
both microscopy and culture. At the end of treatment, mycological cure was 
achieved in 83 patients (75.5%) in the 14-day fluconazole group and in 93 
patients (84.5%) in the single-dose fluconazole group. Mycological failure was 
observed in 27 patients (24.5%) in the 14-day fluconazole treatment group and 
in 17 patients (15.5%) in the single-dose fluconazole group. There was no 
significant difference in mycological cure rates between patients receiving the 2 
fluconazole regimens (OR, 1.780; 95% CI, 0.906-3.496; P = 0.129). The mean 
MICs of fluconazole for these isolates were not significantly different between the 
two treatment groups (P = 0.318). Overall, in 11 patients, clinical cure was not 
achieved, and for all of these, Candida species were isolated from patients’ 
specimens at baseline and on day 14. In 33 patients (15.0%), clinical cure was 
obtained despite persistent positive culture results on day 14 (mycological 
failure).  
 
Relapse. Relapse was analyzed in the 194 patients who completed the follow-up 
phase of the study. The reasons for discontinuation during the follow-up phase 
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were death related to advanced stage of HIV infection and AIDS (4 patients), loss 
to follow-up (11 patients), and administration of additional treatment for OPC 
because of failure to the primary therapy (11 patients). No difference was 
observed in relapse rates among the evaluable patients from the 14-day and 
single-dose fluconazole groups (OR, 1.073; 95% CI, 0.456-2.523; P = 0.99) 
(table 2). The average time to relapse after clinical cure was 20 days (range, 7 – 
30 days) in the 14-day fluconazole group, compared with 18 days (range, 14 –30 
days) in the single-dose fluconazole group. Twenty-two (91.7%) of 24 patients 
who experienced relapse during follow-up had CD4 cell counts <200 cells/mm3, 
16 (66.7%) had CD4 cell counts <100 cells/mm3, 17 (70.8%) were not receiving 
HAART, and 14 (58.3%) had previous episodes of OPC.  
 
 
 
Table 2. Evaluation of relapse of OPC during follow up period among 194 patients 
randomized to a single-dose (750 mg) or 14-days course (150 mg once daily) of 
fluconazole 
 
      No. (%) of patients 
 
     Fluconazole  Fluconazole  Total 
Recurrence    14-days course single dose    
Evaluable patients   100   94   194 
OPC relapse    12 (12%)  12 (12.8%)  24 
(12.4%) 
No relapse    88 (88%)  82 (87.2%)  170 (87.6) 
 
 
OR = 1.073; 95% CI = 0.456-2.523; p = 1.000 (Fisher’s exact test) for the difference in 
OPC relapse between 14 days dose and single dose fluconazole. 
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Fluconazole plasma concentrations. The mean plasma fluconazole 
concentrations on days 1, 4 or 5, 7, and 14 in the 14-day fluconazole group were 
4.18, 6.88, 7.94 and 7.62 mg/L, respectively; for the single-dose fluconazole 
group, the concentrations were 13.35, 5.46, 1.37, and 0.32 mg/L, respectively 
(figure 1). There were statistically significant differences in mean plasma 
concentrations between the two treatment groups on days 1, 7, and 14, but not 
on day 4 or 5 (figure 1). Fluconazole exposure was greater for patients who 
received the single dose of fluconazole, at least until day 4 or 5, compared with 
those who received the 14-day course. 
 
 
 
 
 
Figure 1: Plasma fluconazole concentrations in HIV-positive patients with OPC treated 
with a single-dose (750 mg) and 14-days course (150 mg once daily) of fluconazole. 
Plasma concentrations were significantly different on days 1, 7 and 14 (P<0.01), but not 
on day 4 (P=0.23). 
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Safety analysis. Overall, adverse events were mild, and no differences in 
frequency of adverse events were noted between patients in the 2 treatment 
regimens. Adverse events were reported in 6 patients (5.5%) in the 14-day 
fluconazole group; all events were gastrointestinal. In the single-dose fluconazole 
group, adverse events were reported in 8 patients (7.3%); 6 reported nausea, 
vomiting, abdominal pain, and/or diarrhea, 1 patient had headache, and 1 
patient had palpitations and dizziness. Because most of the study patients were 
in advanced stage of HIV infection and AIDS, abnormalities in full blood count 
and liver function tests were common (table 3). However, no clinically significant 
changes in full blood count and liver function parameters were observed after 
treatment in either of the 2 treatment groups, with the exception of 1 patient 
(0.9%) in the single-dose fluconazole group in whom ALT and AST levels rose to 
262 U/L and to 377 U/L, respectively without symptoms; later, ALT and AST 
levels returned to normal. This patient was taking the study drug while HAART 
(stavudine, lamivudine, and nevirapine) was initiated concomitantly. None of the 
patients discontinued therapy because of adverse events related to the study 
drug. 
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Table 3. Baseline and post treatment haematology and biochemical test results between 
HIV-positive patients with OPC treated with a single-dose (750 mg) and 14-days course 
(150 mg once daily) of fluconazole 
 
     Treatment group 
   14-day fluconazole  SDo fluconazole   
   Baseline Day 14 Baseline  Day 14  P-valuea 
   Mean  Mean  Mean  Mean 
Haematology 
Leucocytes (K/µL) 5.04  4.61  5.05  4.52  0.612 
Erythrocytes (M/µL) 3.99  4.04  4.03  4.08  0.893 
Haemoglobin (g/dL) 10.49  10.76  10.51  10.91  0.740 
Platelets (K/µL)  292.1  286.4  303.6  300.4  0.428 
ESR (mm/hr)  72  49  68  51  0.260 
Biochemical 
ALP (U/L)  109.7  109.3  97.7  102.8  0.955 
ALT (U/L)  24.1  27.6  23.5  31.3  0.134 
AST (U/L)  33.2  33.6  33.7  36.6  0.320 
BilD (mmol/L)  3.7  3.1  3.23  3.4  0.185 
BilT (mmol/L)  7.4  6.4  7.14  6.39  0.987 
LD (U/L)  277.8  279.3  281.7  275.4  0.535 
Urea (mmol/L)  3.6  3.4  3.7  3.6  0.109 
Uric acid (mmol/L) 0.29  0.24  0.27  0.26  0.360 
 
 
a P -value based on F tests, the test is based on the linearly independent pair wise 
comparisons among the estimated marginal means 
 
 
Discussion 
The results of the present study demonstrate that a single-dose regimen of 750 
mg was as effective as a standard 14-day fluconazole regimen in achieving 
clinical and mycological cure in the treatment of OPC in patients with HIV 
infection and AIDS. These results are in agreement with previous studies 
conducted to assess the clinical and mycological efficacy of 14-day fluconazole 
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for management of OPC in patients with HIV infection and AIDS, which 
demonstrated 87%–100% effectiveness in obtaining a complete clinical response 
(9–14). The mycological cure rate, with a single-dose treatment of 750 mg 
fluconazole, was much higher (84.5%) than the 6%–41% mycological cure rates 
reported elsewhere (15–17) that made use of a single dose of 150 mg of 
fluconazole. C.albicans was the species most commonly isolated at baseline, at 
end of therapy, and during OPC recurrence for both treatment groups. In 
addition, plasma fluconazole concentrations on day 1 were significantly higher in 
patients receiving single-dose fluconazole; however, until day 4 or 5, fluconazole 
exposures were similar in both treatment groups. In this trial, similar efficacy 
was found in maintaining a symptom-free period after the end of therapy in both 
treatment groups. OPC relapses were observed (12.4%) in both treatment 
groups, with majority occurring among patients who had low CD4 cell counts 
(<200 cells/mm3), had previous episodes of OPC, and were not receiving HAART. 
Antifungal prophylaxis for these patients may be considered in addition to the 
provision of HAART (12,21).  In addition, both treatments had acceptable 
treatment tolerability and safety.  However, it was demonstrated that ALT and 
AST levels after initiation of HAART among HIV-infected patients who 
concurrently received nevirapine and fluconazole were not different from levels of 
those who received nevirapine-based HAART without fluconazole (22). The 
elevation ALT and AST levels that was observed in one patient in the single-dose 
group in the present study could be attributable to the effect of the nevirapine 
component of the regimen, because liver toxicity caused by nevirapine is well 
known (23,24).   
 
In the present study, reduced susceptibility to fluconazole at baseline was found 
to be a significant factor associated with treatment failure, irrespective of the 
treatment regimen used. For fluconazole, several studies have shown a 
correlation between in vitro susceptibility and treatment outcome (25–27), and 
interpretative breakpoints have been established (28). Our study also indicates 
that MIC testing of isolates at the time of OPC diagnosis might be useful in 
patient management for identification of those patients with an increased 
probability of experiencing treatment failure. 
The high percentage of patients receiving HAART who presented with OPC may 
suggest that the HAART regimens were not effective. However, a recent study 
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conducted at the same hospital as our study and that involved some of our 
patients found high patient compliance to therapy and extremely low rates of 
resistance to HAART (29). The most plausible explanation is that more than one-
half of the patients (55%) were receiving HAART for <3 months, and the 
majority (86.3%) had low CD4 cell counts (<200 cells/mm3). 
 
The use of a single high dose of fluconazole for the treatment of OPC in patients 
with HIV infection and AIDS presents the advantages of simplicity and 
convenience, thus improving compliance and reducing the cost of therapy. A 
single dose of five 150-mg tablets is less costly than fourteen 150-mg tablets 
taken over a 14-day course and, therefore, could be used, especially in resource-
limited settings like in sub-Saharan Africa. In addition, administration of the 
single-dose therapy can be observed directly by medical personnel, thereby 
assuring patient compliance. 
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Abstract 
In HIV-infected individuals the occurrence of oropharyngeal candidiasis (OPC) in 
combination with HIV disease progression is a very common phenomenon. 
However, not all HIV-infected patients develop OPC, even when they develop low 
CD4+ T cell counts. Therefore, insights into the mechanism of susceptibility 
towards OPC during HIV-infection are warranted. In this study, we aimed to 
investigate whether genetic variations in TLR4, MAL and caspase-12 are 
associated with the presence of OPC in HIV-infected subjects from East-Africa. 
The analysis revealed that no difference in the frequency of the studied 
polymorphisms could be observed. These data were complemented by functional 
studies showing that cytokine production measured after whole blood 
stimulations with heat-killed C.albicans was independent of the presence of TLR4 
and Caspase-12 polymorphisms. These data demonstrate that common 
polymorphisms of TLR4 and Caspase-12 in East-Africa do not influence 
susceptibility to OPC in HIV-infected patients. 
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Introduction 
 
Candida albicans is an ubiquitous dimorphic fungal microorganism, often 
commensally colonizing the gastrointestinal and reproductive tracts. The 
commensal carriage of C.albicans elicits and sustains an acquired immune 
response, including the production of C.albicans antigen specific IgA and IgG 
antibodies (1). Infection by Candida spp. in the mouth and upper digestive tract, 
designated as oropharyngeal candidiasis (OPC), is a very common mucosal 
infection in individuals that are infected with human immunodeficiency virus 
(HIV). OPC is an opportunistic infection, almost entirely caused by C.albicans and 
occurs in about 50 to 95% of all HIV-seropositive patients at least once during 
their progression to AIDS (2–4). In many patients, OPC is often the first clinical 
sign of HIV-seropositivity and is included in the clinical staging system of the 
World Health Organization (WHO). Recently, a significant improvement in 
morbidity rates was observed after the introduction of highly active antiretroviral 
therapy (HAART) (5–7). OPC remains however the most frequent HIV-associated 
oral disease in Sub-Saharan Africa where access to HAART may still be limited.   
 
Historically it is well established that low CD4+ T cell counts are a major 
determinant for the occurrence of OPC in HIV-infected subjects (8). A critical 
threshold in this respect is 200 cells/µl. This knowledge is supported by the fact 
that an effective immune response towards C.albicans is known to be Th1 cell 
dependent. Furthermore, in vitro peripheral blood mononucleated cells (PBMCs) 
stimulated with C.albicans antigens are known to respond with the production of 
Th1 cytokines (9,10). However, not all patients with low CD4+ T cell counts 
display OPC, while others with relatively high T cell counts do suffer from OPC. 
These observations suggest that the susceptibility to OPC in HIV-infected patients 
cannot be fully ascribed to the impaired acquired immune response (i.e. low 
CD4+ T cell counts) and point towards an important role for the innate immune 
cells that reside in the mucosal layers of the upper digestive tract. 
 
Recognition of C.albicans by the innate immune system and subsequent 
induction of pro-inflammatory cytokines is mediated by a broad panel of pattern 
recognition receptors (PRR), recognizing conserved bacterial and fungal motifs 
called pathogen-associated molecular patterns (PAMPs). These PRR include Toll-
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like receptors (TLRs), such as TLR2, -4 and -6, and lectin receptors (LRs) like 
dectin-1 and the mannose receptor (reviewed in (11)). Intracellular signaling of 
the TLRs mentioned is mediated by several adaptor molecules, such as MyD88 
(myeloid differentiation primary response gene 88) and MAL (MyD88 adapter-
like, also known as TIRAP) that positively regulate transcription factor activation 
and are crucial for downstream signaling (reviewed in (12)). 
 
Single nucleotide polymorphisms (SNPs) in TLRs and their adaptor molecules 
have been reported to influence the susceptibility towards infectious diseases. 
For instance, the TLR2 T597C SNP has been demonstrated to increase 
susceptibility to tuberculous meningitis (13) and another SNP in TLR2, R753Q, 
has shown to predispose to Candida sepsis (14). Similarly, TLR4 polymorphisms 
D299G alone or in co-segregation with T399I are reported to account for higher 
susceptibility to Gram-negative osteomyelitis (15), disseminated candidiasis 
(16), pulmonary aspergillosis (17) and tuberculosis (18). The MAL variant S180L 
is correlated with resistance to various bacterial infections and malaria (19). 
Another well characterized SNP, in Caspase-12, has been suggested to modulate 
proinflammatory cytokine responses (20), and protects against mortality due to 
sepsis. The full length active form of caspase-12 is believed to be able to cleave 
caspase-1 and thereby dampen the activation of the inflammasome, important 
for processing and activation of interleukin (IL)-1β that is being induced by TLR 
mediated pathways (20). A genetic variant of Caspase-12, which is due to an 
introduction of an early stopcodon, leads to a non-functional protein and is, by 
positive evolutionary selection, fully fixated in the Caucasian population. This is 
possibly due to increased inflammatory responses resulting in sepsis resistance 
(21). However, the ancestral long variant is still present in African populations, of 
which 20% express the active variant of caspase-12. 
 
Whether TLR4, MAL and Caspase-12 SNPs modulate the host defense against 
C.albicans is largely unknown. Moreover, the role of these polymorphisms in 
determining the susceptibility of HIV-seropositive patients towards OPC has not 
been studied to date. In the present study we hypothesized that single nucleotide 
polymorphisms (SNPs) in TLR4 (D299G, rs4986790 and T399I, rs4986791), MAL 
(S180L, rs8177374) and/or Caspase-12 (T/C, nucleotide 125) contribute to the 
susceptibility of HIV-seropositive patients towards oropharyngeal candidiasis in 
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an HIV/AIDS condition and that this correlates with differential cytokine 
production capacity induced after in vitro stimulation of PBMCs with C.albicans. 
 
Patients, materials and methods 
Study design, patients and setting  
The role of the various polymorphisms in the susceptibility to OPC was assessed 
in a group of 99 HIV-seropositive patients. An independent physician, who 
categorized them in accordance with the WHO clinical staging criteria (22), 
performed clinical examination of all study patients. A standard oral examination 
method recommended by WHO was used (23). The intraoral tissues were 
examined for changes in size, colour and shape of anatomical areas as well as for 
clinical signs of OPC. Among them, 55 patients had OPC and 44 patients never 
have developed OPC. Participants were recruited at the Muhimbili National 
Hospital (MNH) HIV-clinic in Dar es Salaam, Tanzania, from April 2007 until 
August 2007. Clinical manifestations of OPC in these 55 patients were 
pseudomembranous candidiasis only (65%), or a combination of 
pseudomembranous and erythematous, hyperplastic or angular cheilitis. In one 
subject only angular cheilitis was observed. OPC clinical score indicated that 95% 
had moderate to severe infections. Other clinical characteristics of the patients 
are presented in Table 1. The functional consequences on the effect of the 
various SNPs on the capacity of cytokine production were investigated in a group 
of 48 African healthy volunteers who were not infected with HIV. 
 
 
Blood collection and CD4+ T cell counts 
Five ml blood samples were collected from patients and transferred to EDTA 
tubes. The same day cell pellets were separated and enumeration of CD4+ T 
cells was done using a flow cytometry count machine after staining patients’ 
blood with anti-CD4 monoclonal antibodies (24).  
 
DNA isolation and SNP detection 
DNA was isolated from whole blood by using the isolation kit Puregene (Gentra 
Sytems, Minneapolis, MN, USA), according to the manufacturers’ protocol. 
Detection of the SNPs in TLR4, Caspase-12 and MAL was performed as described 
earlier (16,19,20).  
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In vitro whole blood stimulation 
Blood was collected from 48 volunteers by venous puncture and was stimulated 
with 106/ml heat-killed (incubated for 30 min. at 56°C) C.albicans for 24 hours at 
37°C. After stimulation, concentrations of the cytokines TNFα, IL-1β, IFNγ and 
IL-10 were measured by ELISA, all purchased from R&D Systems, Inc. 
(Minneapolis, MN, USA), according to the manufacturer's protocol.  
 
Ethical issues 
The ethics committee of the Muhimbili University of Health and Allied Sciences 
(MUHAS) and Muhimbili National Hospital, Dar es salaam, Tanzania approved the 
study protocol. All participants gave informed written consent. The following 
information was given to ensure that patients had the information needed to 
make an informed choice: a complete description of the aim of the study, 
potential benefits and risks, blood collection procedures and assurance of 
confidentiality of any information given as well as test results. Study personnel 
provided any other requested additional information to patients. All patients seen 
in this study received appropriate care and treatment according to national 
guidelines on care and treatment of HIV-infected individuals. All patient 
information and test results were confidentially kept. 
 
Statistical analysis 
Statistics on the CD4+ T cell counts and on the cytokine measurements were 
performed by using the SPSS program (Rel. 14.0.2, 2006; SPSS, Chicago, IL), 
and differences were tested by the Mann–Whitney U test. P < 0.05 was 
considered to represent a statistically significant difference. 
 
Results 
The influence of TLR4, MAL and Caspase-12 polymorphisms on OPC. 
As shown in Table 2, the frequency of TLR4 D299G was exactly equal between 
patients with and without OPC. The TLR4 T399I was absent in the cohort. A very 
low frequency was obtained for the MAL S180L SNP, only two heterozygotes and 
one homozygote for the genetic variant. No statistical analysis on this MAL SNP 
could therefore be performed. Although some differences were detected 
regarding Caspase-12 SNP frequencies (12.7% versus 15.9%) in HIV-
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seropositive patients with and without OPC, the differences were not statistically 
significant. In order to exclude that different CD4+ T cell counts may have been 
a confounder for the role of the various SNPs, we compared CD4+ T cell counts 
in individuals bearing the various polymorphisms (Table 3). The OPC negative 
group had a higher average CD4+ T cell count, as expected (see Table 1). This 
remained the same after splitting the two groups into smaller subgroups with the 
same genotype, showing that TLR4 and Caspase-12 polymorphisms did not 
influence CD4+ T cell counts. 
 
 
Table 1. Clinical characteristics of the 99 Tanzanian HIV-seropositive patients. The 
applied HAART treatment was a cocktail of different reverse transcriptase inhibitors, in 
most cases stavudine, lamivudine and nevirapine, received by 86% of treated patients 
 
 
Patient subgroup OPC positive (n=55) OPC negative 
(n=44) 
Age (mean (range)) 35 (19-63) 34 (21-61) 
Gender (male- female) 10-45 9-35 
HAART use (number (%)) 31 (56.4%) 12 (27.3%) 
Duration of HAART use (months (range)) 12 (1-40) 13 (2-29) 
CD4+ T cell counts (median (± SD)) 101 (±123) 265 (±224) 
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Table 2. SNP frequencies in TLR4, Caspase-12 and MAL in the Tanzanian HIV cohort 
 
Polymorphis
m 
OPC 
status 
Total Homozygo
us 
wildtype 
Heterozyg
ous 
Homozyg
ous 
mutant 
Allele 
frequencies 
Wildtype     
Mutant 
OPC 55 50 (90.9%) 5 (9.1%) 0 95,5% 4,5% TLR4 D299G 
No OPC 44 40 (90.9%) 4 (9.1%) 0 95,5% 4,5% 
OPC 55 41 (74.6%) 14 (25.5%) 0 87.3% 12.7% Caspase-12 
S/L No OPC 44 31 (70.5%) 12 (27.3%) 1 (2.3%) 84.1% 15.9% 
OPC 55 54 (98.2%) 1 (1.8%) 0 99.1% 0.9% MAL S180L 
No OPC 44 42 (95.5%) 1 (2.3%) 1 (2.3%) 96.6% 3.4% 
 
 
 
 
Table 3. Comparison of CD4+ T cell counts in the OPC positive and OPC negative group, 
also stratified by the genotype. Values are median ± SD 
 
Polymorphis
m 
 No. of 
patients 
No. of male 
patients 
CD4 in patients 
with OPC 
(cells/µl) 
CD4 in patients 
without OPC 
(cells/µl) 
 Overall 99 19 101 ±123 265 ±224 
WT/WT 90 19 112 ± 126 260 ± 212 TLR4 D299G 
299/WT 9 0 102 ± 111 298 ± 373 
S/S 72 13 149 ± 130 255 ± 164 
S/L 26 6 56 ± 93 271 ± 338 
Caspase-12 S/L 
L/L 1 0  535 
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The functional effects of TLR4 and Caspase-12 polymorphisms on 
cytokine production. 
In order to link these genotype data to functional consequences regarding 
cytokine production capacity, in vitro stimulations with heat killed C.albicans in 
whole blood were performed in a group of healthy volunteers. No significant 
differences in cytokine production could be detected after comparing stimulation 
of cells from volunteers homozygous for the wild-type genotype with stimulation 
of cells from volunteers either heterozygous or homozygous for the variants of 
TLR4 (Figure 1) or Caspase-12 (Figure 2). Also in this cohort, the T399I SNP was 
completely absent. 
 
We have identified one subject homozygous for TLR4 299G, who had lower 
cytokine production compared to wild-type and heterozygous individuals for all 
four cytokines tested. In contrast, the one individual homozygous for the long 
form of caspase-12 produced normal amounts of cytokines upon stimulation with 
heat-killed C.albicans.  
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Figure 1: Cytokine concentrations measured after 24 hours at 37°C of whole blood 
stimulation with 106/ml heat-killed C.albicans in blood collected from 48 volunteers, 
corrected for background. Cytokines were detected by ELISA. Results are stratified by 
TLR4 D299G genotype (44 homozygous for the wild-type allele, 3 heterozygous and 1 
homozygous for 299G). Values are mean ± SD.  
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Figure 2. Cytokine concentrations measured after 24 hours at 37°C of whole blood 
stimulation with 106/ml heat-killed C.albicans in blood collected from 48 volunteers, 
corrected for background. Cytokines were detected by ELISA. Results are stratified by 
Caspase-12 genotype (26 homozygous for the short variant S, 21 heterozygous and 1 
homozygous for the long variant L). Values are mean ± SD. 
 
 
S/S S/L L/L
0
1000
2000
3000
4000
5000
6000
T
N
F
αα αα
 (
p
g
/m
l)
S/S S/L L/L
0
50
100
150
200
250
300
350
IL
-1
ββ ββ
 (
p
g
/m
l)
S/S S/L L/L
0
10
20
30
40
50
60
70
80
90
IF
N
γγ γγ
 (
p
g
/m
l)
S/S S/L L/L
0
25
50
75
100
125
IL
-1
0
 (
p
g
/m
l)
 122 
Discussion 
In the present study we have investigated the role of genetic variants of TLR4, 
MAL and Caspase-12 for the susceptibility to OPC in HIV-seropositive patients. 
No correlations were found between TLR4 and Caspase-12 polymorphism 
heterozygosity and susceptibility to OPC in a cohort of East-African patients. No 
conclusion can be drawn regarding the involvement of MAL S180L, since this SNP 
was present in too low frequency. 
 
Host defense to C.albicans in general, and OPC in particular, is believed to be 
dependent on a combination of innate and acquired immune responses. The 
importance of the latter has become apparent during the AIDS pandemics, in 
which OPC is one of the most common opportunistic infections. However, the 
variations in the susceptibility to OPC between individuals with low CD4+ T cell 
counts suggest an important role for innate immune responses. This is supported 
by the fact that the C.albicans infection remains restricted to the mucosal layers 
and that disseminated candidiasis in HIV-seropositive patients is rare. Finally, 
oral burdens of C.albicans are shown to be augmented in HIV-infected patients 
even prior to the first episode of OPC (25,26) and before a decline in CD4+ T cell 
count can be observed. 
 
Variations in TLRs and the TLR pathways are considered to be important. As 
mentioned before, SNPs in TLR4, MAL and Caspase-12 are demonstrated to 
influence the susceptibility to different infectious diseases (15–21). However, in 
this study no association could be established between heterozygosity for TLR4 
299G or Caspase-12 long form and susceptibility to OPC. The TLR4 T399I and the 
MAL S180L were respectively not and with low frequency detected in this 
Tanzanian cohort. The epidemiological data are supported by functional cytokine 
studies, in which no significant differences were observed between individuals 
homozygous for wild-type TLR4 or Caspase-12, and individuals bearing 
polymorphisms in these genes. Interestingly, the release of cytokines, IL-1β in 
particular (Figure 2), is not differentially regulated between individuals with 
different Caspase-12 genotypes. This difference in regulation of IL-1β release 
between different Caspase-12 genotypes was previously suggested by Saleh et 
al. (20). In contrast, our findings bring into question whether human caspase-12 
is involved in modulating IL-1β processing. However, it should be noted that 
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clinical outcome (sepsis versus mucosal candidiasis) and origin of the populations 
(African, Caribbean, African-American and South-African versus East-African) 
differ between the studies.  
 
On the other hand, one individual homozygous for TLR4 299G seemed to produce 
significantly less cytokines compared to wild-type individuals (Figure 1). 
Furthermore, heterozygous individuals for this SNP exhibit a trend to higher TNFα 
production capacity, which is consistent with previous findings (27).  It remains 
to be demonstrated whether this tendency is reproducible in other individuals 
homozygous for the TLR4 299G polymorphism.  
 
A limitation of the present study is the relative low numbers of patients. 
However, although small effects of the studied SNPs cannot be excluded, the 
absence of even a trend towards differences suggests that these polymorphisms 
are not responsible for the susceptibility to OPC in a subgroup of HIV-seropositive 
patients. 
 
The TLR4 polymorphism studied in the present study has been previously 
reported to be associated with disseminated candidiasis (16). However, two 
important differences with the present study are important in this respect. 
Firstly, disseminated candidiasis has a different pathogenesis than OPC, with 
innate responses likely to be more important in systemic candidiasis. Secondly, 
the distribution of the TLR4 SNPs D299G and T399I is different between 
populations in Europe and Africa. In Caucasian populations, from which a cohort 
has been analyzed in the previous study, the D299G and T399I SNPs are in 
complete linkage, determining a different TLR4 haplotype than that in African 
populations in which the T399I SNP is largely absent. The difference in TLR4 
haplotypes (299/399 co-segregation in Europe versus 299 alone in Africa) was 
also demonstrated to have functional consequences for TLR4 signaling, and 
therefore a comparison between the TLR4 polymorphisms between these two 
studies cannot be made (27). 
 
In conclusion, no differences have been observed in the frequency of the studied 
SNPs in the genes encoding TLR4, MAL and caspase-12 in Tanzanian HIV-
seropositive patients with and without OPC. These different genotypes also did 
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not have an effect on cytokine responses after an in vitro challenge with heat-
killed C.albicans. One possible exception may be constituted by individuals 
homozygous for TLR4 299G, which seems to result in a reduced cytokine 
production capacity after C.albicans stimulation. However, the low frequency of 
homozygous individuals in the population studied bearing this SNP precludes us 
to draw any conclusions regarding a putative increase in the susceptibility to 
OPC. Our study does not imply that TLR4, MAL or caspase-12 pathways are not 
important for defense against Candida in OPC, but the SNPs in these genes 
cannot explain differences in the susceptibility to OPC in East-African HIV-
seropositive patients. Further research is warranted to elucidate the underlying 
mechanisms that account for the differential immune competence towards 
C.albicans in severely immunocompromised conditions such as AIDS.  
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CHAPTER 7 
 
Summary, discussion, conclusions, proposal for revision of 
Tanzanian treatment guidelines and avenues for future research 
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Summary and general discussion 
This thesis focusses on clinical and microbiological studies of oropharyngeal 
candidiasis in patients with HIV infection in Tanzania, one of the sub-Saharan 
countries mostly affected by HIV infection (1,2). Oropharyngeal candidiasis is a 
common condition in HIV-infected patients and the studies presented here will 
hopefully contribute to a better understanding and management of these patients 
in Tanzania. 
 
Chapter 1 presents epidemiological data of HIV infections in sub-Saharan Africa 
with a focus on the Tanzanian situation. Oral, oropharyngeal and esophageal 
infections mainly caused by Candida species occur frequently in HIV-infected 
patients. These opportunistic infections are accompanied with pain and 
discomfort which may hinder the intake of food, resulting in increased morbidity 
and reduced length and quality of life. In Tanzania, oral candidiasis is the 
commonest oral lesions encountered in HIV infected patients with a prevalence of 
12% to 44% in the period prior to the antiretroviral therapy era (HAART) (3–5). 
Information is missing regarding the prevalence of oral of manifestations of HIV 
in the present HAART era, the types of Candida species involved, their in vitro 
susceptibility to antifungal agents and commonly used indigenous plant extracts , 
the clinical and mycological outcome effects of different drug regimes, and the 
genetic susceptibility towards OPC of HIV patients  To improve our understanding 
about the occurrence and management of oropharyngeal candida infections in 
HIV-infected Tanzanian subjects, clinical and microbiological studies were 
deemed necessary and the following research questions were formulated:  
 What is the prevalence and types of HIV-related oral lesions between 
children and adult Tanzanian patients on HAART and those not on HAART? 
 What are the etiological agents of OPC and their in-vitro susceptibility 
profiles to antifungal agents? 
 What is the in-vitro antifungal activity of some Tanzanian plants reported 
to be used by traditional healers for treatment of oral candidiasis and 
fungal infections of the skin? 
 What is the clinical and mycological efficacy of two different fluconazole 
dosage regimens (single dose versus standard two weeks dose) for the 
treatment of OPC in HIV infected patients? 
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 What is the role of genetic variations in TLR4, MAL and Caspase-12 
towards presence of OPC in HIV-infected subjects in Tanzania? 
 
 
In chapter 2 the aim was to compare the prevalence and types of HIV-related 
oral lesions in children and adult Tanzanian patients on HAART with those not on 
HAART and to relate the occurrence of the lesions with HAART regimens, clinical 
stage of HIV disease and CD4+ cell counts. 532 HIV infected patients, 51 
children and 481 adults were recruited consecutively at the Muhimbili National 
Hospital HIV clinic from October 2004 to September 2005. Investigations 
included; interviews, physical examinations, HIV testing and enumeration of 
CD4+ T cells. A total of 237 HIV-associated oral lesions were observed in 210 
(39.5%) patients. Overall, oral candidiasis was the commonest oral lesion seen in 
125 (23.5%) patients followed by mucosal hyper pigmentation 25 (4.7%), 
parotid gland enlargement 21 (3.9%) and oral Kaposi’s sarcoma 17 (3.2%). In 
children, parotid gland enlargement was the commonest oral lesion (19.6%), 
followed by oral candidiasis (11.8%), oral Kaposi’s sarcoma (3.9%), oral hairy 
leukoplakia (3.9%), herpes simplex lesions (2.2%) and oral warts was the least 
(2.0%). In adults, oral candidiasis was the commonest (24.7%), followed by 
mucosal hyperpigmentation (5.2%), herpes zoster face and odontogenic abscess 
was the least (0.4% each). Adult patients receiving HAART had a significantly 
lower prevalence of oral lesions, particularly oral candidiasis and oral hairy 
leukoplakia. There was no significant change in occurrence of oral lesions in 
children receiving HAART. The occurrence of oral lesions, in both HAART and non-
HAART patients, correlated with WHO clinical staging and CD4+ counts less than 
200 cells/mm3. Oral lesions were also associated with tobacco smoking. The use 
of traditional medicine among our patients was 11.7%, which is an approximately 
one in eight patient. Although no significant association was found between 
occurrences of oral lesions and use of traditional medicine there is still a need for 
further studies since many people with HIV/AIDS use traditional medicine in 
addition to HAART. 
 
Chapter 3 covers a study that was aimed at determining the species distribution 
of isolates obtained from Tanzanian HIV-infected patients with primary and 
recurrent OPC. For each isolate the susceptibility profiles of six antifungal agents 
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was determined and compared for treatment of naive patients and repeatedly 
antifungal exposed patients. A total of 296 clinical oral yeasts were isolated from 
292 HIV-infected patients with OPC at the Muhimbili National Hospital, Dar es 
Salaam, Tanzania. Identification was performed using standard phenotypic 
methods. Antifungal susceptibility to fluconazole, itraconazole, miconazole, 
clotrimazole, amphotericin B and nystatin was assessed using a broth 
microdilution format according to the guidelines of the Clinical and Laboratory 
Standard Institute (CLSI; M27-A2). The results showed that Candida albicans 
was the most frequent isolated species from 250 (84.5%) patients followed by 
C.glabrata from 20 (6.8%) patients, and C.krusei from 10 (3.4%) patients. No 
significant difference in species distribution was observed between patients with 
primary and recurrent oropharyngeal candidiasis. Only fifteen of the 296 isolates 
(5%) were found to be resistant to fluconazole, while 20 (6.8%) isolates were 
susceptible dose dependent (SDD) and 261 (88.2%) were susceptible to 
fluconazole. Twenty-five (8.4%) isolates were found to be resistant to 
itraconazole, while 26 (8.8%) were SDD and 245 (82.8%) isolates were 
susceptible to itraconazole. Isolates cultured from patients previously treated 
were significantly less susceptible to the azole compounds compared to those 
cultured from antifungal naïve patients. Oral yeast isolates from Tanzania were 
found to have a high level susceptibility to the antifungal agents tested. 
Recurrent oropharyngeal candidiasis and previous antifungal therapy significantly 
correlated with reduced susceptibility to azole antifungal agents. Generally, even 
with the observed reduced susceptibility to azoles among oral yeast isolated from 
patients with recurrent OPC and previous history of antifungal therapy, in the 
present study resistance to antifungal agents among the tested isolates is 
relatively low.  
 
In Tanzania, both rural and urban populations still depend on traditional healers 
for provision of health care. In chapter 4 we assesed the in vitro antifungal 
activity of Tanzanian plant extracts reported to be used by traditional healers for 
the treatment of fungal infections. A total of 65 crude methanol extracts 
belonging to 56 plant species and 38 families were screened using the broth 
microdilution method, according to the guidelines of the Clinical and Laboratory 
Standard Institute (CLSI; M27-A2). The results showed that, among the tested 
plant species, 45% (25 species) showed antifungal activity against one or more 
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of the test yeasts. The most susceptible yeasts were Cryptococcus neoformans, 
followed by Candida krusei, C. tropicalis, and C. parapsilosis. The least 
susceptible were C. albicans and C. glabrata. Strong antifungal activity was 
exhibited by extracts of Clausena anisata Oliv. Stem barks, roots of Sclerocariya 
birrea Sond, leaves of Turraea holstii Gurk, Sterculia africana (Lour) Fiori, Acacia 
robusta subsp. Usambarensis (Taub) Brenan, Cyphosterma hildebrandti (Gilg), 
Desc, Elaeodendron buchannanii (Lows), stem of Acacia nilotica (L.) Wild ex Del, 
stem of Jatropha multifida L., stem of Spirostachys africana Sonder and leaves of 
Pteridium aquilinum (L.) Kuhn. Results of the present study suggest a fairly good 
correlation between traditional therapeutic use and the in vitro antifungal 
activity. These results corroborate the importance of ethnobotanical surveys for 
screening plants as a potential source for bioactive compounds. Hence, these 
could result in discovery of novel antifungal agents.   
 
Chapter 5 reports the results of a prospective, randomized, double-blind, 
double-dummy trial that compares the clinical and mycological responses, 
relapse rates and safety of fluconazole given as a single dose or in a multiple 
dose treatment. A total of 220 HIV-infected patients with clinical and mycological 
evidence of oropharyngeal candidiasis were randomly assigned in a 1:1 ratio to 
receive either a 750 mg single-dose of orally administered fluconazole (110 
patients) or 150 mg of orally administered fluconazole once per day for 2 weeks 
(110 patients). The results showed that, single-dose fluconazole was equivalent 
to a 14-day course of fluconazole in achieving clinical and mycological cure, with 
a clinical cure rates of 94.5% and 95.5%, respectively, and a mycological cure 
rate of 84.5% and 75.5%, respectively. No difference was observed in relapse 
rates among the patients from the 14-day and single-dose fluconazole groups. 
The average time to relapse after clinical cure was 20 days (range, 7 – 30 days) 
in the 14-day fluconazole group, compared with 18 days (range, 14 –30 days) in 
the single-dose fluconazole group. Drug-related adverse events were uncommon 
and were not different between the treatment groups, all of them being 
gastrointestinal including nausea, vomiting, abdominal pain and diarrhea. 
 
In HIV-infected individuals the occurrence of oropharyngeal candidiasis in 
combination with HIV disease progression is a very common phenomenon. 
However, not all HIV-infected patients develop OPC, even when they have low 
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CD4+ T cell counts. Therefore, insights into the mechanism of susceptibility 
towards OPC during HIV-infection are warranted. Chapter 6 describes an 
investigation to assess whether genetic variations in TLR4, MAL and caspase-12 
are associated with the presence of OPC in HIV-infected subjects from Tanzania. 
The analysis revealed that no difference in the frequency of the studied 
polymorphisms could be observed. These data were complemented by functional 
studies showing that cytokine production measured after whole blood 
stimulations with heat-killed C.albicans was independent of the presence of TLR4 
and Caspase-12 polymorphisms. These data demonstrated that common 
polymorphisms of TLR4, MAL and Caspase-12 in Tanzania do not influence 
susceptibility to OPC in HIV-infected patients. 
 
Conclusions 
1. Advent of highly active antiretroviral therapy (HAART) has significantly 
reduced the prevalence of oral lesions in adult HIV-infected patients in 
Tanzania, similar to the developed world. However, oropharyngeal 
candidiasis continues to be the commonest HIV-associated oral lesion in 
adults and the second commonest oral lesion in children. 
2. C.albicans is the most frequently isolated species from both patients with 
primary and recurrent OPC. Oral yeast isolates from Tanzania have high-
level susceptibility to antifungal agents. Recurrent OPC and previous 
antifungal therapy significantly correlated with reduced susceptibility to 
azole antifungal agents (fluconazole, itraconazole, miconazole, and 
clotrimazole).  
3. Methanol extracts of some of the herbal plants used by traditional healers 
have shown promising in vitro antifungal activity against yeasts. 
4. A single dose of 750 mg of fluconazole was safe, well tolerated and as 
effective as a standard 14-day fluconazole therapy in patients with HIV 
infection and AIDS with OPC coinfection and may be a favourable regimen 
for moderate to severe OPC. 
5. The common polymorphisms of TLR4, MAL and Caspase-12 in Tanzania do 
not influence susceptibility to OPC in HIV-infected patients. 
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Proposed treatment guidelines: 
On the basis of literature reports and the present studies, more specified 
guidelines for treatment of Candida infections in HIV-infected subjects in 
Tanzania are hereby proposed. Topical treatment of initial episodes of OPC is 
appropriate, provided that clinical symptoms are not severe and there is no 
risk of esophageal involvement. Systemic therapy with oral azoles or 
amphotericin B could be reserved for use in more serious cases of OPC such 
as those unresponsive to topical therapy or involving concurrent esophageal 
candidiasis. Patients with oropharyngeal and esophageal candidiasis are 
treated differently and can be distinguished on basis of their complaints. 
Unlike patients with OPC, complaints of dysphagia, odynophagia and 
retrosternal pain characterize the presence of esophageal candidiasis. No 
resistance can be expected when patients are treated for a fungal infection 
the first time or, possibly, in case they responded previously well to 
treatment.  
 
Treatment guidelines for oropharyngeal and esophageal Candida 
infections in adult HIV-infected subjects 
 
1. Oropharyngeal candidiasis 
a. Mild/moderate:  
i. No resistance suspected: Topical treatment with the following 
antifungal agents is proposed. 
1. Miconazole ointment or cream 2%, apply 5-10 ml after 
food 4 times daily for 14 days, retain in the mouth for 
at least 2 minutes before swallowing.   
2. Clotrimazole oral troches, 10 mg dissolved in mouth 5 
times daily for 14 days, retain in the mouth as long as 
possible. 
3. Nystatin oral suspension, swish 5 ml retain in mouth as 
long as possible, then swallow, 4 times daily for 14 
days. 
ii. No response to local treatment: 
1. Fluconazole tablets single dose of 750 mg or 150 
mg/day orally for 14 days. 
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b. Moderate/severe:  
i. No resistance suspected: 
1. Fluconazole tablets single dose of 750 mg or 150 
mg/day orally for 7-14 days. 
ii. No response to above treatment: 
1. Fluconazole tablets 300-450 mg/day orally for 7-14 
days. 
2. Fluconazole suspension 300-450 mg day orally for 7-
14 days 
3. Itraconazole capsules 200 mg/day orally with meal 
for 7-14 days. 
2. Esophageal candidiasis:  
a. No resistance suspected: 
1. Fluconazole tablets 150 mg/day orally for 14 days. 
2. Itraconazole capsules 200 mg/day orally with meal 
for 14 days. 
b. No response to above treatment: Amphotericin B intravenous 
infusion, approximately 0.3 mg/kg per day for 14 – 21 days. 
 
 
Avenues for future research 
1. In the present studies some of patients on HAART presented with OPC 
which may suggest that the anti-retroviral regimens are not effective 
either because of resistance or non-compliance. Much has to be done to 
determine the usefulness of OPC as a marker for failing HAART. 
2. To determine the efficacy and tolerability of amphotericine B suspension 
for treatment of refractory oropharyngeal and esophageal Candida 
infection. 
3. The use of traditional medicine among patients with HIV infection and 
AIDS patients in our study was high (11.7%) and many use traditional 
medicine in addition to HAART. There is a need to determine the potential 
interactions between traditional and complementary medicine with drugs 
that are used for management of HIV infection and AIDS and its 
associated opportunistic diseases. 
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4. Methanol extracts of some of the herbal plants used by traditional healers 
have shown promising in vitro antifungal activity against yeasts. It is 
crucial to learn more about the nature and composition of these plant 
medicines and bio-guided fractionation with different solvents need to be 
conducted for roots of Sclerocarya birrea Sond, leaves of Acacia robusta 
subsp. Usambarensis (Taub) Brenan, Turraea holstii Gurk, Agauria 
salicifolia, Sterculia africana (Lour) Fiori, Cyphosterma hildebrandtii (Gilg), 
Elaeodendron buchannanii (Lows) and stem of Spirostachys africana 
Sonder to identify the active compounds and structural elucidation. In 
addition, as methanol extraction might only provide a proportion of active 
compounds, water extracts of the herbal plants could be investigated in 
order to establish the presence of water soluble active compounds. 
5. To determine drug-drug interactions between single high dose fluconazole 
with nevirapine containing HAART. 
6. Polymorphisms of TLR4, MAL and Caspase-12 in Tanzania do not influence 
susceptibility to OPC in HIV-infected patients. However further studies are 
needed to determine other functional polymorphisms such as Dectin-1 
Ile177Ser and C/T (3’ UTR) on susceptibility towards development of OPC 
in HIV-infected patients. 
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CHAPTER 8 
 
Samenvatting, discussie, conclusies, voorstel voor 
herziening van behandelingsrichtlijnen in Tanzania en opties 
voor toekomstig onderzoek 
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Samenvatting en algemene discussie 
Dit proefschrift richt zich op klinisch en microbiologisch onderzoek van 
candidiasis in de oropharynx (OPC) bij HIV-geïnfecteerde patiënten in Tanzania, 
een van de landen beneden de Sahara  die getroffen  is door HIV-infectie1,2. OPC 
is een veelvoorkomende aandoening bij HIV-geïnfecteerde patiënten en het hier 
gepresenteerde onderzoek draagt hopelijk bij tot een beter inzicht in en 
behandeling van OPC bij patiënten in Tanzania. 
 
Hoofdstuk 1 presenteert de epidemiologie van HIV-infecties in Afrika beneden 
de Sahara, toegespitst op de situatie in Tanzania. Infecties van mond, keel en 
slokdarm voornamelijk veroorzaakt door Candida species worden frequent 
aangetroffen bij HIV-geïnfecteerde patiënten. Deze opportunistische infecties 
gaan gepaard met pijn en ongemak die voedselopname kunnen belemmeren wat 
leidt tot toegenomen morbiditeit, kortere levensduur en mindere kwaliteit van 
leven. In Tanzania is orale candidiasis de meest voorkomende aandoening in 
HIV-geïnfecteerde patiënten met een prevalentie van 12% tot 44% in de periode 
voorafgaand aan de therapie met anti-retrovirale middelen (highly active anti-
retrovial therapy, HAART)3-5. Gegevens ontbreken over de prevalentie van orale 
HIV-aandoeningen gedurende HAART, over de desbetreffende Candida species, 
hun in-vitro gevoeligheid voor fungicide en veel gebruikte inheemse 
plantenextracten, over de klinische en mycotische effecten van verschillende 
medicamenteuze kuren, en over de genetische predispositie voor OPC van HIV-
patiënten. Om ons inzicht in het voorkomen en het behandelen van candidiasis in 
de oropharynx bij  HIV-geïnfecteerde Tanzanianen te vergroten, werd klinisch en 
microbiologisch onderzoek noodzakelijk geacht. De volgende onderzoeksvragen 
werden geformuleerd:  
• Wat is de prevalentie van HIV-gerelateerde mondaandoeningen bij 
Tanzaniaanse kinderen en volwassenen die HAART krijgen en bij hen die 
dat niet krijgen en welke types aandoeningen zijn er? 
• Wat zijn de agens die OPC veroorzaken en wat zijn hun fungicide in-vitro  
gevoeligheidsprofielen? 
• Wat is de in-vitro fungicide werking van sommige Tanzaniaanse planten  
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waarvan bekend is dat ze gebruikt worden door traditionele genezers voor 
de behandeling van orale candidiasis en mycose van de huid? 
• Wat is de klinische en fungicide werking van twee verschillende fluconazol 
kuren (een eenmalige dosis versus de gebruikelijke kuur van twee weken) 
bij behandeling van OPC in HIV-geïnfecteerde patiënten?  
• Wat is de invloed van genetische variaties in TLR4, MAL en Caspase-12 op 
de aanwezigheid van OPC bij HIV-geïnfecteerde Tanzanianen? 
 
In hoofdstuk 2 werd beoogd de prevalentie en de types HIV-gerelateerde orale 
aandoeningen te vergelijken bij Tanzaniaanse kinderen en volwassenen patiënten 
die HAART kregen en bij degenen die geen HAART kregen. Daarnaast werd 
beoogd verband te leggen tussen aandoeningen optredend tijdens HAART, de 
klinische stadia van HIV en het aantal CD4+ cellen. 532 HIV-geïnfecteerde 
patiënten, 51 kinderen en 481 volwassenen, namen deel aan het onderzoek. Zij 
werden achtereenvolgens verzameld in de HIV-kliniek van Muhimbili National 
Hospital tussen oktober 2004 en september 2005. Het onderzoek hield in: 
vraaggesprekken, lichamelijk onderzoek, testen op HIV en bepaling van het 
aantal CD4+ cellen. Bij 210 patiënten (39.5 %) werden in totaal 237 HIV-
gerelateerde orale aandoeningen geconstateerd. Over het geheel genomen was 
candidiasis de meest voorkomende orale aandoening bij 125 (23.5%) patiënten, 
gevolgd door hyperpigmentatie van de mucosa bij 25 (4.7%), vergrote glandula 
parotis bij 21 (3.9%) en oraal Kaposi sarcoom bij 17 (3.2%) patiënten. Bij 
kinderen was een vergrote glandula parotis de meest voorkomende orale 
aandoening (19.6%), gevolgd door orale candidiasis (11.8%), oraal Kaposi 
sarcoom (3.9%), oraal hairy leukoplakie (3.9%), en herpes simplex 
aandoeningen (2.2%). Orale wratten kwamen het minst voor (2.0%). Bij 
volwassenen werd orale candidiasis het meest gezien (24.7%), gevolgd door 
hyperpigmentatie van de mucosa (5.2%). Herpes zoster van het aangezicht en 
odontogene abcessen kwamen het minst voor (beide 0.4%). Volwassen patiënten 
die HAART kregen vertoonden significant minder orale aandoeningen, met  name 
minder orale candidiasis en minder hairy leukoplakie. Bij kinderen die HAART 
kregen, was er geen significant verschil met betrekking tot de aanwezigheid van 
orale aandoeningen. De aanwezigheid van orale aandoeningen bij patiënten die 
HAART kregen en bij hen die dat niet kregen, was gecorreleerd met de klinische 
stadia van HIV, gehanteerd door de WHO en aantallen CD4+ cellen minder dan 
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200 cellen/mm3. Mondaandoeningen waren ook geassocieerd met het roken van 
tabak. Van onze patiënten gebruikte ongeveer een op de acht (11.7%) 
traditionele medicijnen. Hoewel er geen significant verband werd gevonden 
tussen de aanwezigheid van orale aandoeningen en het gebruik van traditionele 
medicijnen is verder onderzoek toch gewenst aangezien veel HIV/AIDS-patiënten 
die traditionele medicijnen gebruiken ook HAART krijgen. 
 
Hoofdstuk 3 bestrijkt een onderzoek dat tot doel had de speciesverdeling vast 
te stellen van stammen geïsoleerd uit Tanzaniaanse HIV-geïnfecteerde patiënten  
met primaire en recidiverende OPC. Van iedere geïsoleerde stam werd het 
gevoeligheidsspectrum voor zes fungiciden bepaald en vergeleken voor  
behandeling van patiënten die voor het eerst en patiënten die herhaaldelijk  
fungicidemedicatie hebben gehad. In totaal werden er 296 candidamonsters 
genomen van 292 HIV-geïnfecteerde patiënten met OPC uit het Muhimbili 
National Hospital, Dar es Salaam, Tanzania. Voor het identificeren werd gebruik 
gemaakt van standaard fenotypering . Om de gevoeligheid voor fluconazol, 
itraconazol, miconazol, clotrimazol, amfotericin B en nystatin vast te stellen werd 
een verdunningsreeks volgens de richtlijnen van het Clinical and Laboratory 
Standard Institute (CLSI; M27-A2) gebruikt. De resultaten toonden dat Candida 
albicans het vaakst werd geïsoleerd, te weten bij 250 (84.5%) patiënten, gevolgd 
door C. glabrata bij 20 (6.8%) patiënten en C. krusei bij 10 (3.4%) patiënten. Er 
werd geen significant verschil in de speciesverdeling gezien tussen patiënten met 
primaire en recidiverende candidiasis. Van slechts 15 van de 296 geïsoleerde 
stammen (5%) werd resistentie tegen fluconazol vastgesteld, terwijl 20 (6.8%) 
stammen dosisafhankelijke gevoeligheid vertoonden (SDD) en er 261 (88.2%) 
stammen gevoelig waren voor fluconazol. Vijfentwintig (8.4%) geïsoleerde 
stammen bleken resistent tegen itraconazol, terwijl er 26 (8.8%) 
dosisafhankelijke gevoeligheid vertoonden en er 245 (82.8%) gevoelig waren 
voor itraconazol. Geïsoleerde stammen van eerder met fungicide behandelde 
patiënten waren significant minder gevoelig voor azolen  dan stammen van niet 
eerder behandelde patiënten. Geïsoleerde stammen uit Tanzania bleken in hoge 
mate gevoelig voor de onderzochte fungiciden. Recidiverende OPC en eerdere 
fungicidemedicatie waren significant geassocieerd met verminderde gevoeligheid 
voor azolen. In het algemeen is in het huidige onderzoek, zelfs bij de gevonden 
verminderde gevoeligheid voor azolen van geïsoleerde stammen bij patiënten 
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met recidiverende OPC en bij eerder met fungicide behandelde patiënten, de 
resistentie tegen fungiciden relatief laag.  
 
In Tanzania is de bevolking van zowel het platteland als van de stedelijke 
gebieden voor de gezondheidszorg nog altijd afhankelijk van traditionele 
genezers. In hoofdstuk 4 hebben we de in-vitro fungicidewerking van 
Tanzaniaanse plantenextracten bepaald waarvan bekend is dat ze door 
traditionele genezers gebruikt worden bij de behandeling van schimmelinfecties. 
Een totaal van 65 methanolextracten van 56 plantenspecies en 38 families 
werden onderzocht met een verdunningsreeks volgens de richtlijnen van de 
Clinical and Laboratory Standard Institute (CLSI; M27 – A2). De 
onderzoeksresultaten lieten zien dat van de onderzochte plantenspecies er 25 
species (45%) werkzaam waren tegen een of meer onderzochte gisten. De meest 
gevoelige gisten waren Cryptococcus neoformans, gevolgd door Candida krusei, 
C. tropicalis, en C. parapsilosis. De minst gevoelige waren C. albicans en C. 
glabrata. Sterke fungicidewerking lieten extracten van de schors van Clausena 
anisata Oliv. zien, van de wortels van Sclerocariya birrea Sond, bladeren van 
Turraea holstii Gurk, Sterculia africana (Lour) Fiori, Acacia robusta  supsp. 
Usambarensis (Taub) Brenan,  Cyphosterma hildebrandti (Gilg) Desc, 
Elaeodendron buchannanii (Lows), de stengel van Acacia nilotica  (L.) Wild ex 
Del, de stengel van Jatropha multifida L., de stengel van Spirostachys africana 
Sonder en de bladeren van Pteridium aquilinum (L.) Kuhn. Resultaten van de 
huidige studie suggereren een redelijk goede correlatie tussen traditionele 
therapeutische toepassing en de in-vitro fungicidewerking. Deze resultaten 
onderschrijven het belang van botanische verkenningen van inheemse planten 
die mogelijk biologisch actieve stoffen bezitten. Zij kunnen leiden tot de 
ontdekking van nieuwe fungiciden. 
 
Hoofdstuk 5 doet verslag van de resultaten van een prospectief, 
gerandomiseerd, dubbelblind, placebo gecontroleerd klinisch experiment waarin 
de klinische en mycotische respons worden vergeleken, de mate van recidief en 
de veiligheid van een behandeling met fluconazol in een enkele dosis of multipele 
dosis. In totaal werden 220 HIV-geïnfecteerde patiënten met duidelijke klinische 
en mycotische verschijnselen van OPC, 1 op 1 gerandomiseerd, waarbij de ene 
groep een eenmalige orale dosis van 750 mg fluconazol (n = 110) kreeg en de 
 144 
andere groep dagelijks oraal gedurende twee weken 150 mg fluconazol (n = 
110). De resultaten lieten zien dat een eenmalige dosis fluconazol hetzelfde 
effect had als de 14-dagen durende fluconazolkuur op de genezing van de 
klinische verschijnselen (94.5% and 95.5%, respectievelijk) en op de genezing 
van de mycose (84.5% en 75.5%, respectievelijk). Er werd geen verschil 
geconstateerd in de mate van recidief bij patiënten die een eenmalige dosis 
kregen en bij hen die een 14-dagen kuur kregen. Recidief na klinische genezing 
trad na gemiddeld 20 dagen op (variërend van 7 tot 30 dagen) bij de groep die 
14 dagen fluconazol had gekregen en 18 dagen (variërend van 14 tot 30 dagen) 
bij de groep die een eenmalige dosis fluconazol kreeg. Bijwerkingen traden 
zelden op en als ze optraden waren het bij beide groepen maagdarmklachten 
waaronder misselijkheid, overgeven, abdominale pijn en diarree.  
 
OPC in combinatie met progressieve HIV komt veel voor. Toch ontwikkelen niet 
alle HIV-geïnfecteerde patiënten OPC, zelfs niet als ze een laag CD4+ getal 
hebben. Daarom is het belangrijk inzicht te verkrijgen in wat de gevoeligheid 
voor OPC bepaalt bij HIV-infectie. Hoofdstuk 6 beschrijft een onderzoek waarbij 
het ging om vast te stellen of genetische variaties in TLR4, MAL en Caspase-12 in 
verband te brengen zijn met de aanwezigheid van OPC bij HIV-geïnfecteerde 
Tanzanianen. De analyse onthulde dat er geen verschil kon worden 
waargenomen in de frequentieverdeling van TLR4, MAL en Caspase-12. Deze 
uitkomsten werden gecomplementeerd door studies naar de cytokineproductie 
gemeten na bloedcontact met door hitte gedode C. albicans. Het bleek dat de 
cytokineproductie niet afhankelijk was van de aanwezigheid van TLR4 en 
Caspase-12. Deze bevindingen laten zien dat TLR4, MAL en Caspase-12, de 
gevoeligheid voor OPC in HIV-geïnfecteerde patiënten in Tanzania niet 
beïnvloeden. 
  
Conclusies 
1. De komst van HAART heeft de prevalentie van mondaandoeningen bij 
volwassen HIV-geïnfecteerde patiënten in Tanzania significant verlaagd, 
vergelijkbaar met de afname in ontwikkelde landen. OPC blijft echter de 
meest voorkomende met HIV samenhangende mondaandoening bij 
volwassenen. Bij kinderen komt deze aandoening op de tweede plaats. 
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2. C.albicans is de meest frequent geïsoleerde species zowel bij patiënten 
met primaire OPC als bij patiënten met recidiverende OPC. Candida 
stammen in Tanzania hebben een grote gevoeligheid voor fungicide. 
Recidiverende OPC en eerdere medicatie met fungicide waren significant 
geassocieerd met verminderde gevoeligheid voor azolen (fluconazol, 
itraconazol, miconazol en clotrimazol). 
3. Methanolextracten van sommige kruidenplanten gebruikt door traditionele 
genezers lieten veelbelovende in-vitro fungicide werking zien tegen gisten. 
4. Een enkele dosis van 750 mg flucanazol was veilig, werd goed verdragen 
en was even effectief als een standaard fluconazolkuur van veertien dagen 
bij HIV/AIDS-patiënten met OPC. Een enkele dosis zou een te prefereren 
kuur kunnen zijn voor zowel matige als ernstige OPC. 
5. TLR4, MAL en Caspase-12, die veel in Tanzania voorkomen, hebben geen 
invloed op de gevoeligheid voor OPC in HIV-geïnfecteerde patiënten. 
  
Voorgestelde richtlijnen voor behandeling: 
Op basis van de literatuur en het huidige onderzoek worden op deze plaats beter 
omschreven richtlijnen voorgesteld voor de behandeling van Candida infecties in 
HIV-geïnfecteerden in Tanzania. Topische behandeling van beginnende OPC is 
adequaat, mits de klinische symptomen niet ernstig zijn en er geen risico is op 
uitbreiding naar de slokdarm. Systemische therapiën bestaande uit oraal 
toegediende azolen of amfotericine B kunnen gereserveerd worden voor gebruik 
bij ernstiger gevallen van OPC, bijvoorbeeld bij ongevoeligheid voor topische 
therapie of als er zich candididasis van de slokdarm ontwikkelt. Patiënten met 
candidiasis van mond en keel of candidiasis van de slokdarm kunnen worden 
herkend aan hun klachten en ondergaan verschillende behandeling. Anders dan 
klachten van patiënten met OPC, zijn klachten over dysfagie, odynofagie en 
retrosternale pijn karakteristiek voor de aanwezigheid van slokdarmcandidiasis. 
Resistentie valt niet te verwachten als patiënten voor de eerste keer behandeld 
worden voor een schimmelinfectie of, mogelijk als zij eerder goed op de 
behandeling reageerden. 
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Behandelingsrichtlijnen voor candidiasis van mond en keel en 
candidiasis van de slokdarm bij HIV-geïnfecteerde volwassenen 
 
1.Candidiasis van mond en keel 
a. Mild/matig: 
i. Niet verdacht op resistentie: topische behandeling met de 
volgende fungiciden wordt aanbevolen: 
1. Miconazolzalf of crème 2%, 5-10 ml aanbrengen na het eten en 
minimaal 2 minuten in de mond houden alvorens het door te 
slikken, 4X daags gedurende 14 dagen.   
2. Clotrimazol tabletten, 10 mg laten oplossen in de mond en zo 
lang mogelijk in de mond houden, 5x daags gedurende 14 
dagen.   
3. Nystatin drankje, met 5 ml zo lang mogelijk de mond spoelen, 4x 
daags gedurende 14 dagen. 
ii. Geen response bij topische behandeling: 
1. Fluconazol tabletten, eenmalige dosis van 750 mg of 150 mg/dag 
oraal  gedurende 14 dagen. 
b. Matig/ernstig: 
i. Niet verdacht op resistentie: 
1. Fluconazol tabletten, eenmalige dosis van 750 mg of 150 mg/dag 
oraal gedurende 14 dagen. 
ii. Bovengenoemde behandeling slaat net aan: 
1. Fluconazol tabletten, 300-450 mg/dag oraal gedurende 7-14 
dagen.  
2. Fluconazol oplossing, 300-450 mg/dag oraal gedurende 7-14 
dagen. 
3. Itraconazole capsules, 200 mg/dag oraal met de maaltijd 
gedurende 7-14 dagen.   
2.Candidiasis van de slokdarm: 
a. Niet verdacht op resistentie: 
1. Fluconazol tabletten, 150 mg/dag oraal gedurende 14 dagen.     
2. Itraconazole capsules, 200 mg/dag oraal gedurende 14 dagen. 
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b. Bovengenoemde behandeling slaat niet aan: 
1. Amfotericine B, dagelijks ± 0.3 mg per kilo lichaamsgewicht 
intraveneus infuus gedurende 14-21 dagen. 
  
Opties voor toekomstig onderzoek 
1. In het huidige onderzoek hadden enkele patiënten die HAART kregen toch 
OPC wat er op lijkt te wijzen dat de antiretrovirale kuur niet aanslaat of 
door resistentie of door onvoldoende therapietrouw. Er moet nog veel 
onderzoek gedaan worden voordat we weten of OPC een uiting is van 
falende HAART. 
2. Het vaststellen van de werkzaamheid van amfotericine B en de mate 
waarin het verdragen wordt bij de behandeling van recidiverende 
candidiasis van mond, keel en slokdarm.  
3. Het gebruik van traditionele medicijnen onder HIV/AIDS-patiënten in ons 
onderzoek was groot (11.7%) en vele gebruikten traditionele medicijnen 
naast HAART. Er bestaat behoefte aan onderzoek naar de mogelijke 
interacties tussen traditionele en aanvullende medicatie die gebruikt 
worden voor de behandeling van HIV/AIDS en de daarmee geassocieerde 
opportunistische ziektes. 
4. Methanolextracten van sommige kruidenplanten die traditionele genezers 
gebruiken, toonden veelbelovende in-vitro fungicidewerking tegen gisten. 
Het is cruciaal meer te weten te komen over de eigenschappen en 
samenstelling van deze medicinale planten en het biochemisch opwerken 
met verschillende oplosmiddelen waarbij het gaat om de wortels van 
Sclerocarya birrea Sond, bladeren van Acacia robusta subsp. 
Usambarensis (Taub) Brenan, Turraea holstii Gurk, Agauria salicifolia, 
Sterculia africana (Lour) Fiori, Cyphosterma hildebrandtii (Gilg), 
Elaeodendron buchannanii (Lows) en de stengel van Spirostachys africana 
Sonder om de de werkzame bestanddelen in handen te krijgen en om 
meer inzicht te verkrijgen in de struktuur van deze stoffen. Daarnaast 
zouden waterextracten van de kruidenplanten onderzocht kunnen worden 
op de aanwezigheid van in water oplosbare werkzame bestanddelen 
aangezien methanolextractie slechts een deel van de actieve bestanddelen 
zou kunnen opleveren.  
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5. Het bepalen van de wisselwerking tussen een eenmalige hoge dosering 
van fluconazol met HAART die nevirapine bevat. 
6. Polymorfie van TLR4, MAL en Caspase-12 in Tanzania heeft geen invloed 
op de gevoeligheid voor OPC bij HIV-geïnfecteerde patiënten. Verder 
onderzoek is echter gewenst om vast te stellen of andere bestaande 
polymorfie zoals van Dectin-1 Ile177Ser en C/T (3`UTR) invloed heeft op 
de gevoeligheid voor het ontwikkelen van OPC bij HIV-geïnfecteerde 
patiënten. 
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Muhtasari 
Tasnifu hii inaangalia tatizo la ugonjwa wa utando mweupe kinywani unaowapata 
watu waliopungukiwa na kinga ya mwili kutokana na kuwa na virusi vya UKIMWI 
katika Tanzania, ambayo ni mojawapo ya nchi zilizo kusini mwa jangwa la Sahara 
zilizoathirika zaidi na maambukizi ya virusi vya UKIMWI. Ugonjwa wa utando 
mweupe kinywani unaosababishwa na vijidudu vya fangasi aina ya Candida ni 
maarufu miongoni mwa wagonjwa wenye virusi vya UKIMWI. Matokeo ya utafiti 
uliopo katika tasnifu hii yanaweza kusaidia uelewa juu ya ugonjwa wa utando 
mweupe kinywani na matibabu yake katika Tanzania. 
 
Sura ya kwanza ni utangulizi unaoonyesha hali ya ukubwa wa tatizo la ugonjwa 
wa UKIMWI katika nchi zilizo kusini mwa jangwa la Sahara kwa kuangalia zaidi 
hali ya maambukizi ya virusi vya UKIMWI nchini Tanzania. Ugonjwa wa utando 
mweupe kinywani unaosababishwa na vijidudu vya fangasi aina ya Candida 
hutokea kwa wingi miongoni mwa wagonjwa wenye virusi vya UKIMWI pia 
huweza kusambaa hadi kwenye koo. Hii husababisha mgonjwa kutojisikia vizuri 
na pengine kusikia maumivu anapokula chakula hivyo huathiri ulaji wa chakula 
na kusababisha mgonjwa kukosa virutubisho muhimu mwilini hali ambayo 
inapelekea mgonjwa kuugua zaidi na hivyo kupunguza urefu wa maisha. Katika 
Tanzania, ugonjwa wa utando mweupe kinywani hutokea kwa wingi zaidi 
miongoni mwa magonjwa ya kinywa kwa wagonjwa wenye virusi vya UKIMWI. 
Utafiti umeonyesha kuwa utando mweupe kinywani kwa wagonjwa hawa una 
ukubwa wa asilimia kati ya 12 hadi 44 kabla ya kipindi cha kuwepo dawa za 
kupunguza makali ya UKIMWI. Katika kipindi hiki tulichonacho sasa cha kuwepo 
dawa za kupunguza makali ya UKIMWI hakuna tafiti za kutosha zilizofanyika 
hapa Tanzania zinazotoa maelezo juu ya magonjwa ya kinywa yanayoambatana 
na maambukizi ya virusi vya UKIMWI. Pia hakuna maelezo ya kutosha juu ya 
aina ya vijidudu vya Candida, usugu wao juu ya dawa za hospitali na mitishamba 
zinazotumika kutibu, na matokeo ya matibabu ya wagonjwa wenye utando 
mweupe kwa dawa zilizopo. Pia hakuna maelezo juu ya sababu za kigenetiki juu 
ya kupata au kutokupata utando mweupe kinywani kwa wagonjwa wenye virusi 
vya UKIMWI.  
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Katika kuendeleza uelewa zaidi kuhusu ugonjwa wa utando mweupe kinywani 
miongoni mwa wagonjwa wenye virusi vya UKIMWI, utafiti zaidi ulihitajika na 
maswali yafuatayo yaliundwa:   
 Nini ukubwa na aina ya magonjwa ya kinywa kwa watoto na watu wazima 
wenye virusi vya UKIMWI wanaotumia na wasiotumia dawa za kupunguza 
makali ya UKIMWI?  
 Vijidudu aina gani vinasababisha utando mweupe kinywani na je, kuna 
usugu wowote wa kimaabara kwa dawa zinazotumika? 
 Je, dawa za mitishamba inayoripotiwa na kutumiwa na waganga wa jadi 
katika kutibu magonjwa ya fangasi ya ngozi na utando mweupe kinywani 
zina uwezo wa kuua au kusitisha ukuaji wa vijidudu vya fangasi kwenye 
maabara? 
 Ni nini uwezo wa dozi mbili za dawa ya fluconazole (dozi ya siku moja tu 
dhidi ya ile ya wiki mbili) katika kutibu fangasi ya kinywa kwa wagonjwa 
wenye virusi vya UKIMWI? 
 Mabadiliko ya kigenetiki katika ‘Toll-like receptor 4’, ‘MyD88 adapter-like’ 
(MAL) na ‘Caspase-12’ yanayotokea kwa binadamu yanasabibisha vipi 
kuwepo au kutokuwepo kwa utando mweupe kinywani kwa wagonjwa 
wenye virusi vya UKIMWI katika Tanzania? 
 
Sura ya pili malengo ya utafiti katika sura hii ilikuwa kulinganisha ukubwa na 
aina ya magonjwa ya kinywa kwa watoto na watu wazima wenye virusi vya 
UKIMWI wanaotumia dawa na wasiotumia dawa za kupunguza makali ya 
UKIMWI. Pia kulinganisha uwepo wa magonjwa ya kinywa na aina za dawa za 
kupunguza makali ya UKIMWI, hatua ya ugonjwa wa UKIMWI na upungufu wa 
kinga mwilini unaopimwa kwa kutumia idadi ya chembechembe za CD4.  
Wagonjwa 532 wenye virusi vya UKIMWI, kati yao watoto wakiwa 51 na watu 
wazima 481 walikubali na kufanyiwa utafiti katika hospitali ya taifa Muhimbili kati 
ya Oktoba 2004 hadi Septemba 2005. Wagonjwa walihojiwa kwa kutumia 
dodoso, walifanyiwa uchunguzi wa afya pamoja na kupimwa virusi vya UKIMWI 
na idadi ya chembechembe za CD4. Jumla ya magonjwa ya kinywa 237 
yaligundulika katika wagonjwa 210 (39.5%). Kwa ujumla utando mweupe 
kinywani uliongoza, ulipatikana kwa wagonjwa 125 (ambayo ni 23.5% ya 
wagonjwa wote), ukifuatiwa na mabaka ya kinywani (hyperpigmentation) 25 
(4.7%), kuvimba kwa tezi za mate za Parotid 21 (3.9%) na kansa ya kinywa ya 
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Kaposis (Kaposi’s sarcoma) 17 (3.2%). Kwa watoto, ugonjwa wa kuvimba kwa 
tezi za mate za Parotid uliongoza ukiwa ni asillimia 19.6, ukifuatiwa na utando 
mweupe kinywani (11.8%), kansa ya kinywa ya Kaposis (Kaposi’s sarcoma) 
(3.9%), mabaka meupe ya kinywa (leukoplakia) (3.9%), vidonda 
vinavyosababishwa na virusi vya Herpes simplex (2.2%) na warts ya kinywa 
(2.0%). Kwa wagonjwa watu wazima, utando mweupe kinywani ndio ulikuwa 
ukiongoza (24.7%). Magonjwa ya kinywa yalipatikana kwa uchache sana kwa 
wagonjwa watu wazima waliokuwa wakitumia dawa za kupunguza makali ya 
UKIMWI. Hata hivyo, kwa watoto hakukuwa na tofauti kubwa katika uwepo wa 
magonjwa ya kinywa kati ya watoto wanaotumia dawa na wale wasiotumia dawa 
za kupunguza makali ya UKIMWI. Uwepo wa magonjwa ya kinywa ulihusishwa na 
upungufu wa kinga mwilini hasa idadi ya chembechembe za CD4 zikiwa chini ya 
200 na uvutaji sigara. Kati ya wagonjwa waliofanyiwa utafiti asilimia 11.7 walikiri 
kutumia tiba za jadi. Ingawa hakuna uhusiano wowote kati ya matumizi ya tiba 
za jadi na uwepo wa magonjwa ya kinywa, utafiti zaidi unahitajika kwani 
wagonjwa wengi wenye virusi vya UKIMWI wanatumia kwa pamoja tiba za jadi 
na dawa za kupunguza makali ya UKIMWI. 
 
Sura ya tatu ni taarifa ya utafiti kuhusu vijidudu vinavyosababisha utando 
mweupe kinywani na usugu wao kwa dawa zinazotumika kuutibu. Jumla ya 
vijidudu 296 vilipatikana kutoka vinywani mwa wagonjwa 292 wenye utando 
mweupe kinywani ambao wana virusi vya UKIMWI baada ya kuoteshwa kwenye 
maabara. Utambuzi wa aina ya vijidudu ulifanywa kwa kutumia njia maalum za 
kimaabara za utambuzi wa vijidudu vya fangasi. Usugu wa vijidudu kwa dawa za 
fluconazole, itraconazole, miconazole, clotrimazole, amphotericin B na nystatin 
ulichunguzwa kwa kutumia maelekezo maalum ya kimaabara (CLSI; M27-A2). 
Utafiti huu unaonyesha kwamba vijidudu vya fangasi aina Candida albicans 
vilipatikana kwa wagonjwa 250 (84.5%) na ndio visababishi vya mara kwa mara 
vya utando mweupe kinywani. Vilifuatiwa na vijidudu aina ya C.glabrata 
vilivyopatikana kwa wagonjwa 20 (6.8%) na C.krusei vilivyopatikana kwa 
wagonjwa 10 (3.4%). Hakukuwa na tofauti yeyote ya mgawanyo wa aina ya 
vijidudu kati ya wagonjwa wenye utando mweupe kwa mara ya kwanza dhidi ya 
wale wenye utando mweupe mara kwa mara. Vijidudu 15 (5%) tu kati ya jumla 
ya vijidudu 296 ndio vilionyesha usugu kwa dawa ya fluconazole. Vijidudu 25 
(8.4%) kati ya 296 vilionyesha usugu kwa dawa ya itraconazole. Vijidudu 
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vilivyopatikana kutoka kwa wagonjwa waliotibiwa kwa dawa za fangasi mara kwa 
mara walionyesha usugu kwa kwa dawa za fluconazole na itraconazole zaidi 
kuliko vijidudu vilivyopatikana kutoka kwa wagonjwa ambao hawakuwahi kupata 
matibabu ya fangasi kabla. Utafiti huu umebaini kwamba dawa zilizotafitiwa hapo 
juu bado zina uwezo wa hali ya juu wa kuzuia vijidudu vya fangasi 
vinavyosababisha utando mweupe kinywani. Pia, ingawa wagonjwa waliotumia 
dawa kabla na wale waliokuwa na utando mweupe mara kwa mara vijidudu 
vimeonyesha  kupungua kidogo kwa uwezo wa dawa za itraconazole na 
fluconazole, lakini usugu bado ni mdogo sana.  
 
Sura ya nne ni taarifa ya utafiti juu ya uwezo wa kuua au kusitisha ukuaji wa 
vijidudu vya fangasi kwenye maabara unaohusu dawa za mitishamba 
zinazotumiwa na waganga wa jadi katika kutibu magonjwa ya fangasi ya ngozi 
na utando mweupe kinywani. Jumla ya dawa za mitishamba 65 zilizochujwa kwa 
kutumia ‘methanol’, ambazo zinatokana na aina 56 ya mimea zilichunguzwa kwa 
kutumia maelekezo maalum ya kimaabara (CLSI; M27-A2). Utafiti umeonyesha, 
kati ya aina ya mimea iliopimwa, aina 25 ya mimea (45%) ilionyesha uwezo wa 
kuua au kusitisha ukuaji wa aina moja au zaidi ya moja ya vijidudu vya fangasi. 
Vijidudu vilivyoathiriwa zaidi na mimea hii ni aina ya Cryptococcus neoformans, 
ikifuatiwa na Candida krusei, C.tropicalis, na C.parapsilosis. Vijidudu 
vilivyoathiriwa kidogo ni C.albicans na C.glabrata. Mimea ifuatayo imeonyesha 
uwezo mkubwa wa kuua na kuzuia ukuaji wa vijidudu vya fangasi; magamba ya 
mche wa Clausena anisata Oliv., mizizi ya Sclerocariya birrea Sond, majani ya 
Turraea holstii Gurk, Sterculia africana (Lour) Fiori, Acacia robusta subsp. 
Usambarensis (Taub) Brenan, Cyphosterma hildebrandti (Gilg) Desc, 
Elaeodendron buchannanii (Lows), miche ya Acacia nilotica (L.) Wild ex Del, 
Jatropha multifida L., Spirostachys africana Sonder na majani ya Pteridium 
aquilinum (L.) Kuhn. Matokeo ya utafiti huu yanaonyesha kuwa baadhi ya 
mitishamba inayotumiwa na waganga wa jadi kutibu magonjwa ya fangasi ina 
uwezo wa kuua au kusitisha ukuaji wa vijidudu vya fangasi. Hii inaonyesha 
umuhimu wa kufanya utafiti zaidi juu ya mitishamba ambayo inaweza kupelekea 
ugunduzi wa dawa mpya za kutibu magonjwa ya fangasi. 
 
Sura ya tano ni taarifa ya matokeo ya utafiti juu ya tiba ya utando mweupe 
kinywani kwa kutumia dozi mbili tofauti za dawa ya fluconazole. Huu ni utafiti 
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uliofuatilia wagonjwa wenye utando mweupe kinywani juu ya matokeo ya 
matibabu. Jumla ya wagonjwa 220 wenye virusi vya UKIMWI waliokuwa na 
utando mweupe kinywani uliohakikishwa kwa uoto wa vijidudu vya fangasi 
kimaabara walijumuishwa katika utafiti. Wagonjwa 110 walipatiwa dawa ya 
fluconazole vidonge 5 wameze kwa mara moja tu (jumla ya miligramu 750) 
‘single dose’ na wagonjwa 110 walipatiwa dawa ya fluconazole wameze kidonge 
kimoja kwa siku (miligramu 150) kwa muda wa wiki mbili (dozi ya wiki mbili). 
Matokeo ya utafiti yanaonyesha kwamba, uwezo wa tiba ya fluconazole ya 
vidonge 5 ‘single dose’ ni karibu sawa na ule wa tiba ya wiki mbili ya fluconazole 
katika kuponya ugonjwa wa utando mweupe kinywani kwa wagonjwa wenye 
virusi vya UKIMWI. Hakuna tofauti katika dozi hizi mbili za fluconazole katika 
kujirudia kwa utando mweupe kinywani baada ya matibabu. Utafiti umeonyesha 
pia kwamba hakuna dalili mbaya ‘drug adverse effects’, baada ya matumizi ya 
dozi hizi za fluconazole na zinaweza kuvumiliwa na wagonjwa ila wagonjwa 
wachache waliopata matatizo kama vile kutapika, maumivu ya tumbo na 
kuharisha. 
 
Sura ya sita: Ugonjwa wa utando mweupe kinywani hutokea sana kwa 
wagonjwa wenye virusi vya UKIMWI ambao kinga ya mwili imeshuka sana (chini 
ya CD4 200), ingawa si wagonjwa wote wanaopata utando mweupe kinywani 
licha ya kinga mwilini kushuka sana. Sura hii inatoa taarifa ya utafiti juu ya 
mabadiliko ya kigenetiki katika ‘Toll-like receptor 4’, ‘MyD88 adapter-like (MAL)’ 
na ‘Caspase-12’ yanayotokea kwa binadamu jinsi yanavyohusiana na kuwepo au 
kutokuwepo kwa utando mweupe kinywani kwa wagonjwa wenye virusi vya 
UKIMWI katika Tanzania. Matokeo yanaonyesha kwamba hakuna tofauti ya 
mabadiliko ya kigenetiki katika Toll-like receptor 4, MAL na Caspase-12 kati ya 
wagonjwa wenye virusi vya UKIMWI walio na utando mweupe kinywani na wale 
wasio na utando mweupe kinywani. Hii inaonyesha kwamba mabadiliko ya 
kigenetiki katika ‘Toll-like receptor 4’, ‘MA’L na ‘Caspase-12’ hayaongezi 
uwezekano wa kutokea au kupata ugonjwa wa utando mweupe kinywani kwa 
wagonjwa wenye virusi vya UKIMWI. 
 
Sura ya saba inajadili na kutoa muhtasari wa tafiti zote zilizopo kwenye tasnifu 
hii. Pia inaelezea majumuisho ya tafiti zote na mapendekezo ya tiba ya ugonjwa 
wa utando mweupe kinywani na kooni kwa wagonjwa wenye virusi vya UKIMWI 
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katika Tanzania. Na mwisho wa sura hii ni mwongozo wa tafiti nyingine ambazo 
zinafaa kufanyika kwa siku za baadaye ili kujibu baadhi ya maswali yaliyojitokeza 
katika tafiti hizi. 
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